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ABSTRACT 
Background 
Cardiovascular disease (CVD) remains the number one killer even after years of 
advances and preventative measures.  Identifying and reducing modifiable risk factors 
is a health care priority.  CVD Risk assessments are calculated using several traditional 
risk factors including age, gender, race, blood pressure, cholesterol, history of diabetes, 
and smoking to estimate a persons’ risk of developing CVD (heart disease or stroke) in 
the next 10-years. In addition to the traditional risk factors for CVD, there is increasing 
evidence of metabolic disorders, depressive symptoms, inflammation and sleep quality 
posing a greater risk for CVD.  However, these factors are not included in the current 
risk prediction models including the Framingham Risk Score, Reynolds Risk Score, and 
Pooled Cohort Risk Equations. Therefore, this study examined the effect of depressive 
symptoms, inflammation, and sleep quality on the independent risk for CVD.  
Objective  
The primary objective of this study was to evaluate the independent relationships 
between traditional cardiac risk factors, depressive symptoms, inflammation, and sleep 
quality, on long-term risk of major adverse cardiovascular events (MACE). The 
secondary objective was to evaluate whether gender modifies the relationships between 
depressive symptoms, inflammation, and sleep quality on long-term risk of MACE. 
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Design  
A secondary analysis was conducted on data obtained from the Longitudinal 
prospective cohort study Heart Strategies Concentrating on Risk Evaluation (Heart 
SCORE) conducted by the University of Pittsburgh. The ongoing Heart SCORE study 
has been prospectively examining cardiovascular disease (CVD) risk factors and CVD 
events on an initial cohort of 2,000 enrolled adults ages 45 to 75 at study entry.  A Cox 
proportional-hazard model was used to evaluate the relationship between traditional risk 
factors as well as independently and collectively for depressive symptoms, inflammation 
and sleep quality and risk of MACE. Models were reanalyzed adding gender as an 
interaction term and in stratified analyses to evaluate whether gender modifies the 
relationships between sleep quality, depressive symptoms, and inflammation and long-
term risk of MACE.   
Results 
The participants (N= 1,895) included in this study were, 1256 females (66%), 639 
males (34%), ranging from 45 to 75 years of age with a median age of 60 years, 42% 
Blacks, 55% Whites and 3% other race. Six percent, (n =113) of the participants 
experienced a major cardiac event during a mean of nearly 10 year follow up. Results 
indicated that men as compared with women with high levels of interleukin-6 had 
particularly high risk for CVD, as defined by two separate definitions of MACE,  MACE1: 
Hazard Ratio (HR) 3.44 vs. 1.72 for males and females, respectively, MACE6: HR 2.51 
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vs. 1.69 for males and females, respectively.  These results suggest the high 
inflammation in men is strongly associated with future risk of CVD. The addition of 
depressive symptoms to the initial traditional risk factor model was associated with a 
modest increase in the risk of both definitions of MACE (HR range from 1.20 to 1.68) 
with similar results observed by gender. Sleep quality/Insomnia was not associated with 
long-term risk of MACE overall or when evaluated separately by gender.   
Conclusion  
Primary prevention with early identification of potential modifiable risk factors is a 
key strategy in planning interventions to reduce the risk of CVD. Results from this study 
suggest that depression and inflammation (e.g. IL-6) should be studied in other 
populations to estimate their independent predictive value in risk stratification. Whereas 
sleep quality was not associated with long-term risk of CVD in this analysis, future 
studies should consider the use of objective measures of sleep quality, such as 
actigraphy in addition to standard use of self-report measures and sleep diaries.   
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CHAPTER ONE:  
INTRODUCTION 
Cardiovascular disease (CVD) is the number one cause of death worldwide, with 
an estimated cost of $316 billion per year (Benjamin et al., 2018). Cardiovascular 
disease is a broad term used to include any ailment of the heart and vascular system 
(Center for Disease Control and Prevention, CDC, 2018). The Agency for Healthcare 
Research and Quality (AHRQ) has elevated cardiovascular disease prevention and 
treatment as national priority in the National Quality Strategy (AHRQ, 2014). The Million 
Hearts Campaign initiative aims to prevent one million heart attacks and strokes over a 
5-year period with an objective to identify and spread better models of care delivery and 
payment (Benjamin et al., 2018).  
Although several multivariable risk estimation scores and equations have been 
derived and published, there are inherent limitations of using the existing scores (Goff et 
al., 2014). In addition, data are sparse on the use and impact of absolute risk scores in 
clinical practice in primary-prevention settings to determine absolute risk score for 
varying populations of the United States (Goff et al., 2014). Risk factor determination 
using the existing CVD risk assessment models may predict the incidence of CVD 
events and mortality. However, many experts believe that there is a need to identify and 
add novel risk markers in short- and long-term risk assessment to determine outcomes 
in all racial/ethnic groups, and across the age spectrum, and in women and men (Lin et 
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al., 2018). The short- and long-term risk assessment in diverse groups will guide 
providers to offer a more personalized approach to patient behavioral and motivating 
interventions, change and adherence to therapy for improving risk factor levels, and 
clinical outcomes (Lin et al., 2018).   
The US Preventive Services Task Force (USPSTF) recently published 
recommendations regarding the use of non-traditional risk factors in CVD risk 
assessment (Curry et al., 2018).  The focus of the most recent recommendations was 
on the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, and 
coronary artery calcium (CAC) score (Benjamin et al., 2018; Curry et al., 2018; Lin et 
al., 2018).  When endorsing change of health benefits, potential harms and cost are 
considered. Although, the impact of these risk factors was not consistent nor significant 
enough to recommend reform from current practice, the potential benefits were 
recognized and may be considered in a more personalized approach for prevention and 
treatment (Benjamin et al., 2018; Curry et al., 2018; Lin et al., 2018).  
Evidence is also emerging that other non-traditional risk factors such as 
depressive symptoms and sleep quality may increase susceptibility and aid in 
subsequent prediction for CVD (Alcantara & Davidson, 2014; Sands-Lincoln et al., 
2013). In general, most cohort studies that assessed risk calibration with the use of 
novel markers found that adding one of the non-traditional risk factors improved 
calibration and potentially better preventive care (Curry et al., 2018). Therefore, using 
existing data set from Heart Strategies Concentrating on Risk Evaluation (Heart 
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SCORE) study, this secondary data analysis focused on examining the contribution of a 
few key non-traditional risk factors, on predicting long-term risk of CVD. 
Background of the Problem 
 National and worldwide initiatives in the development of risk assessment tools 
have resulted in improved treatment guidelines, including use of medications and 
invasive interventions that have played significant roles in the reduction of CVD 
mortality (Benjamin et al., 2018).  Traditionally, prevention and management of CVD 
begins with an assessment to identify the presence of cardiac risk factors (Benjamin et 
al., 2018; Curry et al., 2018). The risk factors are conditions that, on average, make a 
person more likely to develop a disease. Such risk factors for CVD are categorized into 
modifiable or non-modifiable risk factors. Modifiable risk factors for CVD include: high 
blood pressure, diabetes, hypercholesterolemia, obesity, sedentary lifestyle, smoking, 
uncontrolled stress, and unhealthy dietary habits (Benjamin et al., 2018). Age, family 
history of early heart disease and menopause for women are risk factors that cannot be 
changed to reduce the likelihood of CVD, and thus, are termed non-modifiable risk 
factors (Benjamin et al., 2018).   
Primary care providers are responsible for identifying modifiable risk factors and 
management of preventive interventions including education and life-style changes 
(AHRQ, 2014).  However, studies have used different stratum and risk calibration 
approaches to determine risk (Curry et al., 2018).  In this regard, although the addition 
of some non-traditional risk scores improved calibration, there is inconsistent evidence 
as to the benefits of basing therapeutic strategies on some of the non-traditional risk 
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factors for patients; for example, adding statin therapy for patients with elevated hsCRP 
levels (Ridker et al., 2008).  As clinical practice moves toward a single threshold 
(algorithm) for treatment, this concern may no longer be relevant in clinical decision 
making. The USPSTF recommends including more information on the differences 
between commonly used CVD risk assessment tools, as well as population distribution 
of risk (Curry et al., 2018). 
History of Cardiac Risk Assessment 
 The original CVD risk assessment was developed for adults between the ages of 
30 to 62 at the time of first examination, and with no history of heart attack or stroke. 
These assessments were derived from participants enrolled in the Framingham Heart 
Study, which began in 1948 (Kannel, 1976). The Framingham Heart Study, along with 
other important large studies, such as the Seven Countries Study and the Nurses’ 
Health Study, provided the information now known about cardiac risk including healthy 
lifestyle such as healthy diet and regular exercise (Kannel, 1976). Additionally, greater 
knowledge about the differences in cardiovascular risk between men and women were 
gleaned from these studies. The first risk prediction equations demonstrated the 
potential amplified risk when having multiple risk factors such as, hypertension, elevated 
total cholesterol, decreased HDL, smoking, glucose intolerance, and left ventricular 
hypertrophy, versus one risk factor (O’Donnell & Elosua, 2008).  
 The CVD Risk assessments are calculated using several factors including age, 
gender, race, blood pressure, cholesterol, history of diabetes, and smoking to estimate 
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a persons’ risk of developing CVD (heart disease or stroke) in the next 10-years. The 
overall goals of these tools are to assist not only clinicians, but also patients, in 
understanding risk and monitoring over time and quantifying potential benefits of 
preventative therapies (Benjamin et al., 2018; Curry et al., 2018; Lin et al., 2018).  
The Framingham Risk Score  
The Framingham Risk Score (FRS) assessment is a well-known and widely 
accepted tool, developed from the knowledge gained in the long-term Framingham 
Heart Study. The FRS uses a simple point score to provide 10-year estimates of 
myocardial infarction or cardiac mortality (Hermansson & Kahan, 2018). The first 
Framingham risk score was introduced in 1976 and identified risk factors successful at 
predicting 10-year risk for CVD. This study validated non-modifiable risks such as age, 
gender, family history and previous history of cardiac problems and modifiable risk 
factors including smoking, diabetes, hyperlipidemia, and hypertension (Hermansson & 
Kahan, 2018; Kannel,1976).  The Tool was updated in 2002 with the addition of 
dyslipidemia, and in 2008 with the addition of diabetes as a major risk factor 
(Hermansson & Kahan, 2018). The FRS tool has been questioned for its generalizability 
to the general American population, as it was developed and tested on a primarily White 
male population.   
Reynolds Risk Score for Women  
The Reynolds Risk Score for Women (RRSW) was developed to overcome the 
drawback from FRS with gender-specific assessment. The RRSW includes assessing 
activity, lifestyle, and diet, and includes a measure of the inflammatory marker C-
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Reactive Protein (CRP) (Goff et al., 2013). The RRSW was developed from findings of a 
large study with over 24,000 healthy non-diabetic women. These women were followed 
over 10 years and monitored for the development of a major cardiac event (Ridker et 
al., 2007).   
Reynolds Risk Score for Men 
The Reynolds Risk Score for men was developed based on a study following 
over 10,000 healthy non-diabetic men over 10 years. Like the women’s tool, the addition 
of High Sensitive C-Reactive protein (hsCRP) and family history of a major event prior 
to the age of 60 years of age was added to the model improving predictability of CVD in 
men (Ridker et al, 2008).  
Pooled Cohort Equations Risk Estimator 
Through collaborative efforts of the AHA, National Heart, Lung and Blood 
Institute (NHLBI) and The American College of Cardiology, the Pooled Cohort 
Equations Risk Estimator tool was developed to better predict the 10-year risk of 
developing atherosclerotic cardiovascular disease (ASVCD) and how that risk may 
change over time as preventative measures are initiated (Goff et al., 2013). Attention 
was taken to include various races and gender within this study (Goff et al, 2013). The 
Pooled cohort screen is presently recommended as the standard of practice for risk 
screening.  Unlike the Reynolds score but similar to the FRS, the Pooled Cohort 
Equations tool includes diabetes as a risk factor, highlights the large burden of disability 
from non-fatal cardiac events and provide separate equations for non-White 
populations. Yet, given the increased evidence that inflammation plays a crucial role in 
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the process of atherogenesis, the Pooled Cohort Equations do not include CRP or other 
inflammatory markers in risk calculation (Held et al., 2017; Joseph et al., 2017). 
 Many developing countries have developed CVD risk scores specific for their 
region such as the Canadian CVD guideline (Anderson et al., 2012); The European 
Society of Cardiology uses the Systemic Coronary Risk Evaluation (SCORE) risk charts 
(Perk et al., 2012); The UK National Institute for Health and Care Excellence uses the 
QRISK3 risk tool; and The Scottish Intercollegiate Guidelines Network (SIGN) uses the 
ASSIGN risk score to determine the 10-year risk of a CVD events (National Institute for 
Health and Care Excellence (NICE), 2014). These risk assessments tool do not include 
non-traditional risk scores such as hsCRP (Scottish Intercollegiate Guidelines Network 
(SIGN),2017). 
The above-mentioned risk scores are algorithms that enable health care 
providers and patients to estimate 10-year and lifetime risks for atherosclerotic CVD to 
provide preventive services to minimize the risk (Bell & Saraf, 2014). Unfortunately, 
there is insufficient data to reliably predict risk for those less than 40 years of age or 
greater than 79 years of age (Curry et al., 2018). Also, evidence is emerging on the 
association of metabolic disease, depressive symptoms, and sleep quality that 
increases CVD risk, and these are not included in the above risk prediction tools, 
thereby warranting further studies. Thus, this secondary analysis aimed to examine the 
value of these non-traditional risk factors in risk prediction. 
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Problem 
 Despite a wide range of educational programs, national campaigns, increased 
funding and improved screening tools, CVD continues to have very high mortality and 
burden of disability on society. Nearly half of all Americans (44%) have at least one of 
the three key risk factors for heart disease: high blood pressure, high cholesterol, or 
smoking (Benjamin et al., 2018). Moreover, the growing obesity epidemic is associated 
with unhealthy diet, high blood pressure and a dramatic rise in Type 2 diabetes 
(Benjamin et al., 2018). 
 Over the past 2 decades, considerable progress has been made in the reduction 
of CVD related deaths, with a decrease of nearly 3.79% from 2000 to 2011 (Sidney et 
al., 2016). However, the decline flattened around 2011 and remains flattened today 
(Mensah et al., 2017; Sidney et al., 2016). The annual rate of decline for CVD mortality 
between 2000-2011 was 3.79 percent, while the same measures from 2011-2014 were 
only less than one percent (Sidney et al., 2016). The current risk reductions 
recommendations are based mostly on the risk assessment with the Framingham Risk 
Score or Pooled Cohort Equations. Quality studies comparing traditional risk 
assessment with traditional risk assessment together with novel markers such as 
cytokines are needed to measure the potential impact of adding nontraditional risk 
factors on clinical decision thresholds and patient outcomes (Shaima, Vinayaga-Moorthi 
& Kutty-Shaheen, 2016).  
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Purpose 
 Depressive symptoms have been linked to CVD and CVD mortality (Lahtinen et 
al., 2018; Lawes et al., 2018).  Additionally, persons with high levels of inflammatory 
markers and altered sleep quality have also been identified as being at a higher risk of 
CVD (Dhar & Barton, 2016). These modifiable risk factors are not traditionally screened 
for and may contribute to both primary and secondary prevention for cardiac disease 
aimed at reducing risk for CVD and limiting complications, mortality, and disability, 
including among those who have experienced a major adverse cardiac event. 
 The purpose of this secondary data analysis was to evaluate the predictive ability 
of depressive symptoms, inflammation, and sleep quality on CVD risk. An additional 
clinical question was to determine, if screening for these non-traditional modifiable risk 
factors during routine exams, may allow for primary prevention measures that may 
reduce risk of CVD. This included evaluation overall and by gender.  
Specific Aims: 
1. To prospectively evaluate the independent relationships between traditional 
cardiac risk factors, depressive symptoms, inflammation, and sleep quality, on 
long-term risk of major adverse cardiovascular events (MACE). 
2. To prospectively evaluate whether gender modifies the relationships between 
depressive symptoms, inflammation, and sleep quality on long-term risk of 
MACE. 
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Definition of Terms 
 For purposes of this study, the following terms are defined: 
 Cardiovascular Disease  
 Cardiovascular disease (CVD) is a global term that refers to conditions that involve 
the heart and vascular system. This includes a diagnosis of congenital malformations of 
the heart and/or vasculature, hypertension, arrhythmias or irregular electrical activity of 
the heart, valvular heart disease and ischemic heart disease or arthrosclerosis (Benjamin 
et al., 2018). For this study, persons with congenital malformations were not included. 
 Major Adverse Cardiac Event  
Major adverse cardiac event (MACE) is a composite endpoint commonly used in 
research, yet without a standard definition (Kip et al., 2008). The Heart SCORE study 
employed 6 different definitions for MACE. To illustrate a lack of standard definition and 
end points for MACE, deJung et al. (2017) defined "CVD events” as admission for heart 
failure, ischemic cardiovascular events, and cardiac death. In a dissimilar manner, 
Nejatian et al. (2017) defined MACE as a hospital stay with an MI, unplanned 
revascularization including percutaneous coronary intervention, coronary artery bypass 
surgery and all-cause mortality (deJung et al., 2017; Nejatian et al., 2017). Within the 
current analysis, two of the six definitions of MACE were examined, as defined below.  
 MACE1.  MACE1 includes, all cardiac deaths, acute myocardial infarction, (AMI), 
cerebral vascular accident (CVA), acute ischemic syndrome (AIS) and any coronary 
revascularization procedure. 
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 MACE6. MACE6 includes all deaths, acute myocardial infarction, (AMI), cerebral 
vascular accident (CVA), acute ischemic syndrome (AIS). 
Atherosclerosis 
 Atherosclerosis, also known as atherosclerotic heart disease (ASHD), involves a 
buildup of plaque inside arteries leading to a narrowing and stiffening of the vasculature.  
The plaque is made up from cellular waste, fatty deposits, calcium, and fibrin (Benjamin 
et al., 2018). Vascular narrowing slows the flow of oxygenated blood and increases the 
risk of blood clot formation.  Additionally, plaque can break away from the arterial wall, 
increasing risk for a thrombus or obstructed blood flow (Benjamin et al., 2018). 
Atherosclerosis increases risk of organ failure due to diminished oxygenated blood flow.   
Ischemic Heart Disease 
 Ischemic heart disease is a condition in which buildup of plaque within the walls 
of the coronary arteries causes narrowing within the size and compliance of the 
vasculature creating an obstructed blood flow. The reduced blood flow results in 
reduced oxygenation or ischemia to the heart muscle and organs (Benjamin et al., 
2018).  
Cardiac Events  
Cardiovascular events include the diagnosis of death related to cardiac disease, 
myocardial infarction, acute ischemic syndrome, cerebral vascular accident (ischemic), 
and ischemic heart disease requiring revascularization or opening of the arteries to 
increase blood flow.  Ischemic heart disease and cardiovascular events are of interest 
for this study.  
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Myocardial Infarction (MI)   
  The most common cause of an MI is atherosclerosis that has led to a complete 
blockage of blood flow to an area of the heart (Benjamin et al., 2018). Additional 
terminology includes ST-elevation myocardial infarction (STEMI) and non-ST-elevation 
myocardial infarction (NSTEMI). These terms are based on presentation of a MI on an 
electrocardiogram (ECG) (Kumar & Cannon, 2009; Senter & Francis, 2009). 
Revascularization   
Revascularization refers to any medical procedure employed to restore blood 
flow to the heart.  There are several procedures that may fall under this term. 
Angioplasty includes procedures done without open surgery by accessing arteries 
through the skin such as percutaneous transluminal coronary angioplasty (PTCA) and 
arterial stenting.  Additionally, coronary artery bypass (CABG) is a surgical procedure to 
restore blood flow to the heart, falling under the revascularization term (Thygesen, 
Alpert & Harvey 2007).   
Cerebral Vascular Accident   
Cerebral vascular accident (CVA), which is also referred to as a stroke, is a 
condition that occurs when blood flow to the brain is obstructed and the brain is without 
enough oxygen resulting in death of brain cells.  There are 2 categories of stroke based 
on etiological classifications of CVA, including ischemic and hemorrhagic strokes 
(Benjamin et al., 2018; Speranza et al., 2000). 
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Acute Ischemic Stroke  
 Acute Ischemic Stroke (AIS) is caused from narrowing or obstruction of blood 
flow from atherosclerosis or an obstruction caused from a blood clot to the brain. It may 
be transient as from a spasm or a clot that breaks free or minimal blood flow resulting in 
hypoxia to the brain tissue usually without permanent damage; this is referred to as a 
transient ischemic accident (TIA) (Benjamin et al., 2018; Kidwell & Warach, 2003; 
NIHLBI, 2018).  
 Hemorrhagic Stroke  
 Hemorrhagic stroke is caused from bleeding in the brain that may cause 
pressure and/or loss of blood flow to the brain, resulting in damage or death to brain 
cells (NIHLBI, 2018). 
Diabetes 
 Diabetes Mellitus, commonly known simply as diabetes, is a disease in which the 
body’s ability to produce or respond to the hormone insulin is impaired, resulting in 
abnormal metabolism of carbohydrates and elevated levels of glucose in the blood and 
urine (Shoback & Gardner, 2011). It is considered a chronic metabolic disorder in which 
the blood glucose is higher than the acceptable rages of 80-130 mg/dL. This 
hyperglycemic state is a result of pancreas inability to control blood glucose levels. 
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Type I Diabetes  
 Type I diabetes is the result of ineffective secretion of insulin by the pancreas, 
with about 5-10% of all diabetics being type I (American Diabetes Association (ADA), 
2018). Treatment includes daily administration of insulin.   
 Type II Diabetes  
 Type II diabetes is a failure of the pancreas to compensate for a resistance of the 
insulin by the cells resulting in hyperglycemia. Diabetes affects more than 30 million 
people in the United States, and approximately 90% of all cases are classified as Type 
II (ADA, 2010). 
 Gestational Diabetes  
 Gestational diabetes is often temporary and occurs during pregnancy.  With this 
condition, the body is unable to maintain blood glucose levels within an acceptable 
range. Persons having gestational diabetes have an increased risk of developing Type 
II diabetes later in life (ADA, 2010; International Diabetes Foundation (IDF), 2018).   
Depressive Symptoms  
 Symptoms of depression vary, but include loss of interest or pleasure, loss of 
energy, fatigue, sleep problems, and changes in appetite.  Depressive symptoms have 
been linked to physiological changes such as increased inflammatory markers and is 
therefore relevant to this study (Dannehl et al., 2014).  Sometimes, symptoms that look 
like depression are not really depression. Depressive symptoms range in seriousness 
from mild, temporary episodes of sadness to severe, persistent depression. Clinical 
depression is the more-severe form of depression, also known as major depression or 
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major depressive disorder. Clinical depression is a treatable serious medical illness 
according to the American Psychiatric Association (APA, 2015). This paper includes 
persons with depressive symptoms, rather than a diagnosis of clinical depression. 
InInterleukin-6 (IL-6)  
 Interleukin-6 is a measure of inflammation that has an expected value in the 
general population of approximately 1-5 pg/ml. Secretion of IL-6 occurs as an acute 
phase inflammatory response and plays a role in the process that leads to 
atherosclerosis.  IL-6 triggers the liver to produce the inflammatory marker C-reactive 
protein (CRP) (Yudkin, Kumari, Humphries & Mohamed, 2000).  
C-reactive Protein (CRP) 
 C-reactive protein is produced in the liver and adipocytes and is a part of the 
acute phase inflammatory response (Martinez & Gonzalez- Juanatey, 2009).  CRP is a 
non-specific indicator of elevated inflammation that may occur secondary to stress, 
infection, cancer, CVD, rheumatoid arthritis, and trauma (Yudkin, Kumari, Humphries & 
Mohamed, 2000).   
Highly Sensitive C-Reactive Protein (hsCRP) 
Similar to CRP, hsCRP measures more specifically blood vessel CRP and is a 
more specific measure with respect to risk of atherosclerosis. Current recommendations 
for evaluating cardiovascular risks suggest the use of hsCRP. However, this 
assessment may not be cost effective as a high level of accuracy requires multiple 
laboratory measurements, 2 weeks apart, and with the average of the readings used to 
estimate potential cardiac risk (CDC, 2018). 
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Quality of Sleep (Insomnia) 
 Sleep is the natural periodic suspension of consciousness during which the 
powers of the body are restored (Harvey Stinson, Whitaker Moskoviz & Virk, 2008). 
Insomnia refers to habitual sleeplessness or inability to sleep. Quality of sleep is 
measured as insomnia, assessed as the ability to fall asleep or sleep latency, duration 
of sleep and functional ability upon awakening. Quality of sleep has been linked to work 
related injuries and errors, perceived quality of life, as well as physical illness including 
increased inflammatory markers, diabetes, and cardiovascular disease.  Research has 
suggested that sleep of less than six-hours or poor quality of sleep (sleep apnea, for 
example), increases risk for experiencing a cardiac event (Barger et al., 2017). 
Traditional Risk Factors for CVD 
 A risk factor refers to something that increases health risk or susceptibility.  
Below are definitions of several conditions that have been accepted as traditional risk 
factors for CVD (Goff et al., 2014; Lin et al.,2018)  
 Hypertension 
  Hypertension refers to abnormally high arterial blood pressure that is usually 
indicated by an adult systolic blood pressure of 120 mm Hg or greater or diastolic blood 
pressure of 80 mmHg or greater (James et al., 2014; Whelton et al., 2017). Systolic 
blood pressure represents the pressure exerted against arterial walls with each 
heartbeat.  This is the upper number on the blood pressure reading.  The newest 
guidelines recommend systolic blood pressure to be < 120 mm Hg.  Diastolic blood 
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pressure, the lower number of the reading, represents the pressure exerted against the 
arterial walls between heartbeats. Consistent readings over guideline-specific 
recommended levels are consistent with a diagnosis of hypertension (Whelton et al., 
2017). 
 Metabolic Syndrome 
 Metabolic syndrome is a cluster of conditions which include elevated blood 
pressure, high blood sugar, excess body fat around the waist, low HDL (i.e. good 
cholesterol) and high triglyceride levels.  The higher number of these factors and having 
at least 3 of the factors (definition of metabolic syndrome) increases future risk of CVD 
(Zimmet, Alberti & Shaw, 2005).  
 Body Mass Index   
 Body mass index (BMI) is a person’s weight in kilograms divided by the square of 
height in meters (kg/m2). A BMI greater than 25 indicates overweight; greater than 30 is 
classified as obese (WHO, 2014). 
Central Obesity or Abdominal Obesity 
  Central obesity is defined as excessive adipose in the abdominal area and is an 
independent predictor of CVD.  Measures in women greater than 89 centimeters and 
men greater than 102 centimeters portend higher risk for CVD (Canoy et al., 2013).  
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Dyslipidemia 
 Elevation of plasma cholesterol and triglycerides (TG) and low High-Density 
lipoprotein (HDL) cholesterol levels are defined as dyslipidemia, and contribute to the 
development of atherosclerosis (Bear, 2017). Although low HDL levels predict 
cardiovascular risk in the overall population, the increased risk may be caused by other 
factors, such as accompanying lipid and metabolic abnormalities, rather than the HDL 
level itself. Etiology for dyslipidemia can be primary (genetic), or secondary and caused 
by poor lifestyle or dietary practice, as well as some disease conditions (Goff et al., 
2014).  
 Triglycerides (TRIG) 
 Triglycerides carry unused fat cells to be stored and used for energy later.  
Elevated triglycerides have long been considered a risk factor for CVD, and optimal 
levels are less than 150 mg/dL (Baer, 2017; Goff et al., 2014). Elevated triglycerides in 
diabetes increases the risk of CVD (Goff et al., 2014).  
 High Density Lipoprotein (HDL) 
  Low, serum HDL cholesterol is strongly associated with risk factors for CVD. 
This cholesterol is often referred to as the “good” cholesterol as it works to transport fat 
out of the arteries. Anti-inflammatory and antioxidant effects of high HDL levels reduce 
endothelial damage and are favorable in preventing CVD (Goff et al., 2014). 
Recommended values for women are greater than 55mg/dL and men greater than 
45mg/dL (CDC, 2017; Smith et al., 2017). 
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Low density Lipoprotein (LDL) 
  Low-density lipoprotein is often referred to as the bad cholesterol.  Although not 
listed as a component of the metabolic syndrome, elevated LDL plays a key role in the 
development of atherosclerosis and is strongly associated with CVD.  Recommended 
levels for LDL are less than 130 mg/dL, however, more recent guidelines are 
emphasizing lower numbers (<100 mg/dL). These values vary among agencies with 
newer guidelines recommending target values based on risk analysis and comorbidities 
(Baer, 2017; Pallazola et al., 2018).   
Significance to Nursing 
 In the campaign against CVD, primary prevention with early identification of 
potential modifiable risk factors is key in planning interventions to reduce occurrence of 
the disease. CVD has become our Nations’ costliest chronic disease and will continue 
to be the most burdensome disease that Americans will face in the coming decades. 
Thus, expenses associated with CVD are expected to soar in coming years. Therefore, 
identifying the degree to which depressive symptoms, inflammation, and sleep quality 
influence development of CVD may support changes in how routine screenings are 
conducted to better inform and manage CVD risk. This study aimed to address the gap 
in knowledge that exists for the optimal development of appropriate screenings and 
preventative measures to prevent cardiovascular disease.  
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CHAPTER TWO: 
REVIEW OF LITERATURE 
 Scientific evidence supports a strong relationship between a person’s lifestyle 
and risk for developing or dying from CVD. The World Health Organization (WHO) 
estimates that over 75% of premature CVD is preventable and risk factor amelioration 
can help reduce the growing CVD burden among both individuals and healthcare 
providers (Curry et al., 2018; Roth et al., 2017). While a general estimation of the 
relative risk for CVD can be approximated by counting the number of traditional risk 
factors present in a patient, a more precise estimation of the absolute risk for a first 
CVD event is desirable when making treatment recommendations for a specific 
individual.  
 This chapter presents the supporting evidence on the effects of traditional risk 
factors for CVD including; age, race, gender, obesity, smoking, diabetes, hypertension, 
and hyperlipidemia and the risk for developing CVD including the occurrence of a major 
adverse cardiac event (MACE). In addition, literature supporting evidence of interaction 
with demographic variables, as well as evidence on the non-traditional and potentially 
modifiable risk factors of depressive symptoms, inflammation, and sleep quality and 
their relationship to risk for CVD are discussed.   
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Traditional Risk Factors For CVD 
 Age Gender and Race as Risk For CVD  
Age is an independent “non-modifiable” risk factor for CVD and confers 
heightened risk until the approximate age of 70 years when the risks start to level off 
(Dhingra & Vasan, 2012).  Aging is associated with a decline in cellular regeneration, 
respiratory capacity, skeletal muscle decline, reduction in hormones, and a weakened 
and often chronically alarmed immune system (Barzilai, Huffman, Muzumdar, & Bartke, 
2012).  Aging increase ones’ risk for hypertension, visceral adiposity, insulin resistance, 
and atherosclerosis, all considered risk factors for CVD (Lopez-Candales, Hernandez-
Bergos, Hernandez-Suarez & Harris, 2017; Mosca, Barrett-Connor & Wenger, 2011). 
Previous literature has used the term “heart age” to distinguish from chronological age.  
Heart age estimates a person’s age based on the presence of cardiac risk factors.  For 
example, a 45-year-old obese, diabetic individual with hyperlipidemia and hypertension 
would be “older” in heart age than a 50-year-old non-smoker non-diabetic, who is 
overweight by about 10 pounds, and with normal blood pressure and cholesterol levels 
(Hirsch, Wits, Li, & Soliman, 2018; Yang et al., 2015).  The CDC reports that the 
average American male has a heart age nearly 8 years and women 5.4 years greater 
than their true years of age (Hirsch et al., 2018; Yang et al., 2015). Chronological age is 
not modifiable but reducing modifiable risk factors could lower an individual’s heart age.  
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 Prior to reaching age of 45-years, men have a higher rate of hypertension, 
increased arterial stiffness and endothelial dysfunction and nearly double the risk for 
CVD compared to women (Mosco, Barrett-Connor & Wenger, 2011; Benjamin et al., 
2018). Cardiovascular disease develops, on average, 7 to 10 years later in women than 
in men (Maas & Appelman, 2010). As women start to age into the sixties, the rates start 
to even out for women, and those with comorbidities may have a higher risk for CVD 
than men (Benjamin et al., 2018; Mosco et al., 2011;).  These differences could be 
related to female hormones that reduce with age and then cease during menopause.  It 
has been thought that estrogen may have protective components. Rat studies have 
found estrogen to have a significant effect in epithelial homeostasis, anti-fibrotic effects, 
vasodilatation, and a reduction in oxidative stress, all factors directly related to the 
development (or lack thereof) of atherosclerosis (Lorga et al., 2017). Additionally, 
women who experience premature menopause, having lost the protection of estrogen 
before the age of 40, have been found to have a shorter life (Rocca et al., 2012; Sabbag 
et al., 2017). 
 Physiologically, women with CVD react differently and have poorer outcomes 
then men. Women often present with atypical complaints when experiencing an MI and 
have a higher risk of mortality (Sabbag et al., 2017). Symptoms do not always include 
the crushing chest pain, shortness of breath easily recognized as a potential cardiac 
event.  Women complaints can be vague, including, fatigue, diaphoresis, and nausea 
(Mehta et al., 2016; Sabbag et al., 2017). These presentations contribute to delay in 
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medical evaluation and/or misdiagnoses, as women have been found to have higher 
rates of Global Registry of Acute Coronary Events (GRACE) score ≥140 (19% vs 12%, 
p = .007) (Sabbag et al., 2017). Moreover, revascularization procedures may be less 
likely to be successful in women who may have less complete blockages (Merz & 
Chang, 2016; Mehta et al., 2016). Additionally, revascularization procedures have 
increased bleeding complications thought to be related to increased platelet aggregation 
in women (Maas & Appelman, 2010; Mehta et al., 2016). These differences in 
presentation with MACE place women at a higher risk for misdiagnosis, delay of 
treatment, including invasive interventions, and death (Maas & Appelman, 2010; Mehta 
et al., 2016; Merz & Chang, 2016).    
 Historically, CVD risk factors are seen disproportionately in racial and ethnic 
populations (Kurian & Carderelli, 2007). An awareness of the disparities of CVD risk 
factors by race and ethnicity may guide clinicians to develop culturally sensitive 
educational, interventional and prevention programs aimed at risk factors prevalent 
within these populations. Blacks have been considered at higher risk for CVD.  An 
analysis using subject data from both The Mediators of Atherosclerosis in South Asians 
Living in America study and The Multi-Ethnic Study of Atherosclerosis study reported 
Blacks to have more than double the risk for developing atherosclerotic CVD after all 
adjustments, compared to whites, HR 2.23, 95% CI [1.51, 3.30] (Kullo et al., 2007; Rifai 
et al., 2018). Hypertension, diabetes, obesity, and atherosclerosis have a higher 
prevalence at an earlier age in the Black population (Carnethon et al, 2017). According 
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to the American Heart Association (AHA), deaths rates for CVD are 270.6 per 100,000, 
for Non-Hispanic White Males compared with, 356.7 for Non-Hispanic Black males  and 
183.8 for Non-Hispanic White females and 246.6 for Non-Hispanic Black females 
(Benjamin et al., 2018). Cardiovascular related death rates are consistently higher 
among Blacks.  
 Despite this increased rate of mortality in the Black population, Blacks have 
paradoxically been found to have favorable lipid profiles in comparison to Whites.  
Racial differences in lipoprotein levels have previously been reported in the Heart 
SCORE study.  For blacks compared to whites, the breakdown is as follows.  Blacks 
had higher HDL cholesterol levels compared to Whites. Both Black men and Black 
women had fewer small dense LDL particles than their White counterparts (Aiyer, et al., 
2007; Kullo et al., 2007). Similar findings are reported by Gaillard and Osei, (2016), that 
women with an elevated risk of obesity and many with prediabetes were analyzed for 
racial differences.  Blacks with prediabetes were more obese (BMI 38.8 + 6.7 kg/m2 
than White 36.0 +5.4 kg/m2). Also, Blacks had lower triglycerides levels ( 84.4 +47.9 
mg/dL) than Whites (125 +55.5 mg/dL).  Moreover, this study reported higher HDL 
cholesterol levels and higher small sized LDL cholesterol in Black women (Gaillard & 
Osei, 2016). 
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Diabetes as a Risk For CVD 
Diabetes has long been considered a “cardiovascular risk equivalent” and people 
with diabetes have 2 to 4 times increased risk of CVD morbidity and mortality than 
individuals without diabetes (Bertoluci & Zorzanelli, 2017). Younger diabetics such as 
men under the age of 35 years and women under 45 years without a raised LDL 
cholesterol level (more than 100 mg/dL), normotensive with no past cardiac history or 
obesity may not be at a greater risk. It was suggested in determining preventive 
measures, that the need for statin medication should make use of a more individualized 
approach (Bertoluci & Zorzanelli, 2017). The Cardiovascular Health study sought to 
explore differences by gender and race in risk for CVD. Compared to non-diabetics, a 
significant increased risk for CVD was established for Black, diabetic women HR 2.15, 
95% CI [1.43, 3.23] and Black diabetic men HR 1.48, CI 95% CI [0.92, 2.39]. Interaction 
between diabetes, gender, and CVD was not significant (Vimalananda et al., 2014). 
Diabetes has been long linked to CVD. Among those with Type II diabetes, 75% 
or greater of all hospitalizations and more than 50 % of deaths, are related to CVD 
(Benjamin et al., 2018). Diabetics, especially persons with Type II tend to be more 
overweight and have a more sedentary lifestyle in comparison to those without diabetes 
(Dokken, 2008). However, not everyone with diabetes is the same and differences in 
medical and family history, gender, race, and age influence risk. The AHA/ACC have 
suggested that diabetics be stratified for risk based on presence of comorbidities (Goff 
et al., 2014).   
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 The physiological changes associated with diabetes, elevated blood glucose, and 
inflammatory responses place the diabetic individual at greater risk for atherosclerosis, 
which is a major component to CVD.  Vascular endothelium lines the entire circulatory 
system and is responsible for maintaining blood vessel tone including vasodilation and 
constricting, and prevents thrombogenesis and inflammation (Rajendran et al.,2013). 
When blood sugars rise, the normal homeostasis and function of the endothelium is 
altered, and an inflammatory response releasing free radicals leads to the oxidized LDL. 
Diabetics often have an increased low-density lipoprotein (LDL) but smaller in size 
(Dokken, 2008). The smaller LDL are more likely to become oxygenized.  In the effort of 
leukocytes and macrophages to destroy the oxidized LDL, foam cells occur and attach 
to the vascular wall along with LDL cells that lead to atherosclerosis.  The effected 
endothelium is also responsible for platelet activation which is important in clot 
formation.  This alteration in the endothelium may lead to platelet aggregation 
increasing the risk of blood clots forming (Dokken, 2008: Rajendran et al., 2013).   
 The prevalence of depression has been reported as two-fold in diabetics 
compared to non-diabetics (Anderson, Freedland, Clouse, & Lustman, 2001; Badescu 
et al., 2016).  Furthermore, diabetics with depression have a much higher rate of 
atherosclerosis and have been reported to have a 50% increased mortality rate, and 
40% increased rate of CVD over those without depression (van Dooren et al., 2013).  
These alarming findings support the concern for those with the combined effect of 
having diabetes and depressive symptoms being at a greater risk for developing CVD.  
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 The connection between diabetes, hyperglycemia, and atherosclerosis is an 
obvious risk for CVD. Maintaining glucose control through diet, exercise, and taking 
medications as prescribed is imperative for a diabetic to limit these devastating effects.  
Poor medication compliance in diabetes has been shown to increase mortality by 45% 
and risk of a cardiac event by 41% (Kim et al., 2018).   
 Smoking as a Risk for CVD 
 Smoking is a modifiable independent risk factor for CVD.  According to the 
Surgeon General’s Report, smoking is a major cause of CVD and is responsible for one 
in every five deaths (Benjamin et al., 2018). Those who smoke as few as five cigarettes 
a day and nonsmokers, with exposure to secondhand smoke, experience an increased 
risk for CVD compared to nonsmokers (Benjamin et al., 2018). Smoking has a profound 
physiological effect and is estimated to shorten one’s life by 10 years (Jha et al., 2013; 
McBride, 1992). 
 A brief explanation of the pathology of a cigarette will shed light on the effects of 
smoking and the development of CVD.  Upon inhaling a cigarette, the nicotine, 
numerous chemicals and free radicals are not freely accepted, and an acute immune 
response is activated.  The resulting response results in the release of hormones 
including adrenaline and noradrenaline (Powell, 1998). These hormones promote 
vasoconstriction, as well as an increase in heart rate and blood pressure (Gordan, 
Gwathmey & Xie, 2015; McBride, 1992).  Simultaneously the immune response leads to 
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build up of oxidized LDL and foam cells attaching to the endothelium wall (Al-Delaimy et 
al., 2002; Messner & Bernhard, 2014; Morris et al., 2015).  This inflammatory response 
within the endothelium was also described as a response high glucose levels in 
diabetics.  The elevated heart rate and blood pressure increases oxygen demand.  
However, the oxygen carrying erythrocytes have absorbed carbon monoxide (CO) 
inhaled from the cigarette (Powell, 1998).  The CO binds with the oxygen, resulting in 
the erythrocytes carrying carboxyhemoglobin and unable to transport the needed 
oxygen (Powell, 1998). To compensate for the need of oxygen, the body releases 
additional erythrocytes to transport the oxygen.  The excess of erythrocytes referred to 
as erythrocytosis increases the viscosity of the blood which may slow movement 
through veins and arteries and may impede capillary flow completely (Sopori, 2002).  
Additionally, the immune system also initiates platelet aggregation increasing the risk of 
clot formation (Sopori, 2002).   
 A meta-analysis combining 25 separate cohort studies of the CHANCES 
consortium evaluated risk for CVD mortality and events in relation to smoking (Mons et 
al., 2015). Cox proportional hazard regression indicated that the risk was elevated for 
current smokers HR 2.07, 95% CI [1.82, 2.36] and former smokers HR 1.37, 95% CI 
[1.25,1.49]. Similarly, risk for cardiac events for current smokers HR 1.98, 95% CI [1.75, 
2.25] and for former smokers HR 1.18, 95% CI [1.06, 1.32] were elevated (Mons et al., 
2015).    
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Smokers were reported to lose 10 years off their lifespan however, if they quit 
smoking prior to the age of 34 years, recalculated survival analysis indicated life 
expectancy nearly identical to a non-smoker, gaining back 9 years of life.  If one does 
not stop smoking until after the age of 34 years, they will still regain 4-6 years of life 
(Jha et al., 2013). Thus, it is never too late to quit smoking.  Smoking cessation has 
significant benefits including a reported 36% reduction in CVD mortality seen over a 2-
year period for those who quit smoking after having an MI (Rigotti & Clair, 2013). Actual 
benefits of quitting will be affected by how much one smoked on average per day and 
for how many years.  After quitting smoking, risk for CVD drops drastically for the first 4 
years, and then slows beyond that.  (Bullen, 2014; Dresler et al., 2006).  
In summary smoking has a profound effect on endothelial function. The 
constricted vasculature is lined with epithelium that has now has waste products 
attached to its walls, impeding blood flow, and a dysfunctional ability to cause 
vasoconstriction or dilatation (McBride, 1992).  The blood is now thicker and sticky with 
an excess of platelets and erythrocytes and reduced oxygen (Powell, 1998). One can 
visualize how 20-40 cigarettes a day can significantly add to atherosclerosis, blood clots 
or complete occlusions, and as a causal basis for ischemic heart disease.   
 Hypertension as a Risk for CVD 
 Hypertension is quantitatively the most important traditional risk factor for 
premature CVD; it is more common than cigarette smoking, dyslipidemia, and diabetes 
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and accounts for an estimated 47% of all ischemic heart disease events globally (Wong et al., 
2012). Among a large sample of subjects with a diagnosis of hypertension and either high 
Framingham Risk Score (FRS) (>20%), 23% or with prior CVD 32% ; almost two-thirds 
of hypertensive males 61% were found to be in the high-risk CVD groups compared to 
49% of the females (p < 0.001) (Wong et al., 2012). This study also reported that 
Hispanics with a diagnosis of hypertension were less likely to be at higher risk than 
other ethnicities (p < 0.05) (Wong et al., 2012). 
 Racial differences in blood pressure have long been reported with Blacks having 
a higher prevalence and incidence of hypertension, as documented by AHA statistics 
obtained from 2009-2012.   Indeed, an alarming 44.9% of adult Black men and 46.1% 
Black women have been diagnosed with hypertension compared to an overall rate of 
32.6% for the entire US adult population (Mozaffarian et al., 2016). In contrast, The 
Systolic Blood Pressure Intervention Trial (SPRINT) looked at treatment modalities for 
hypertension as well as racial differences.  Systolic BPs in this study were not 
significantly different among the different racial groups of Non-Hispanic White, Non-
Hispanic Black and Hispanics (Still et al., 2018). This result varies from that reported by 
AHA that Non-Hispanic Black have more hypertension and death rates more than 30% 
higher than the general population (Still et al., 2018). In a study of high-risk veterans 
that included 23,955 men and 1,010 women and assessment of three risk factors that 
predispose to CVD (diabetes, hypertension, and hyperlipidemia), average BP was 
reported higher among Blacks comparative to whites.  Black female veterans after age 
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adjustment had estimated mean systolic BPs of 136.3 mmHg as compared to 133.5 
mmHg among white female veterans (p < .01). Mean diastolic BPs for black females 
were 82.4 mmHg versus 78.9 mmHg for white females (p < 0.01) (Goldstein et al. 
2014). Large variations between studies was noted.  It is necessary to continue 
monitoring for age, gender and racial differences. When evaluating population-wide 
blood pressure variation, it is important to include treatment modalities.  In addition, 
future studies using age-adjusted models, models assessing relative risks compared to 
others of same age, and models including thorough assessments of target organ 
damage and ambulatory 24-hour blood pressure are needed to tighten the knowledge 
gap in elucidating differences among different ages, races, and gender.  
 Obesity as a Risk for CVD 
As the prevalence of obesity continues to rise in the United States, the rate of 
CVD and associated complications will also increase. The obesity epidemic has the 
potential to reduce further gains in the US life expectancy, largely through an adverse 
effect on CVD mortality (Benjamin et al., 2018). The CVD risks associated with obesity 
are often assessed using the body mass index and central or abdominal obesity. 
Body Mass Index as a Risk for CVD 
 Body Mass Index (BMI) is a measure of not only height and weight but also 
overall body mass.  BMI is a preferred measure when looking at risk factors as it 
correlates with overall body fat, which is often linked with risk for heart disease (CDC, 
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2013).  The calculation is based on a formula weight/height2 (kg/m2). A healthy BMI is 
(25 kg/m2), increasing BMI is considered a key component to the metabolic syndrome 
(Zimmet, Alberti & Shaw, 2005). A number of studies have documented the association 
between obesity and cardiovascular disease (CVD) risk factors (Freedman, Khan, 
Serdula, Galuska, & Dietz, 2002; Gregg et al., 2005). 
 Central Obesity as a Risk for CVD 
 Central obesity is when body fat is disproportionately distributed in the abdominal 
area, with some describing it as having a pear shape. Central obesity has been found to 
be more predictive of mortality than an elevated BMI (Coutinho et al., 2013). For 
example, men with a normal BMI (this study used < 22 kg/m2 as normal), but with 
central obesity compared to men with an elevated BMI and no central obesity were at 
twice the risk for mortality, HR 2.42, 95% CI, [1.30, 4.53]. This study had comparable 
results among women, with central obesity being the most predictive factor for mortality 
(Sahakyan et al., 2015).  
 Lipid Levels and Risk for CVD 
 Dyslipidemia is a term that refers to elevation of plasma cholesterol, triglycerides 
(TRIGs), or both, or high LDL cholesterol or a low HDL cholesterol level that contributes 
to the development of atherosclerosis. Dyslipidemia is recognized as a prominent risk 
factor for CVD (Miller, 2009). Current guidelines focus on lowering LDL with a statin in 
both primary and secondary prevention, and a consensus statement by Pallazola et al. 
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(2018) reports discordance between established guidelines and global practices. The 
authors who reviewed five guidelines reported differences among major guideline 
committees and recommended addressing beyond risk estimation and aggressive 
management of moderate- to high-risk patients and the need for a unified guideline 
(Pallazola et al., 2018). Therefore, understanding the association between the levels of 
these lipids and CVD risks are important. 
 Triglycerides (TRIG) as Risk for CVD 
 Despite three decades of research, the controversy regarding the relationship 
between triglycerides and risk of CVD persists. Although, earlier cohort studies reported 
a univariate association between TRIG and CVD, this association was no longer 
statistically significant after adjustment for either total cholesterol (TC) or LDL 
cholesterol (Di Angelantonio et al., 2009). Cardiovascular risk was evaluated in a large 
cohort study of American Indians (N= 3216) over 17 years. This study reported that 
elevated TRIG in combination with low HDL increased the risk for developing CVD by 
1.32-fold 95% CI [1.06. 1.64], and having diabetes increased this risk by 1.54% (Lee et 
al., 2017).  After adjusting for covariates, a different study compared those with TRIG 
levels less than 100 mg/dL to those with greater than 500 mg/dL, with those with greater 
than 500 mg/dL being at greater than 60% higher risk of death over 22-years (Klempfer 
et al., 2016).  
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 The Framingham Heart Study found that both genders were at a significantly 
greater risk for developing CVD if there LDL cholesterol level was greater than 
160 mg/dL compared to those with an LDL less than 130 mg/dL, HR 1.74, 95% CI 
[1.36,2.24] for men and HR 1.68, 95% CI [1.17, 2.40] for women (Wilson et al., 1998).   
Similarly, in the Atherosclerosis Risk in Communities (ARIC) study, with a study 
population of over 12,000 middle aged men and women, the risk of coronary heart 
disease was significantly related to LDL levels.  In fully adjusted models including age 
race smoking systolic blood pressure and diabetes the HR for elevated LDL for women 
was significant for men (HR 1.43) and women (HR 1.24) without any previous history of 
CVD (Sharrett et al., 2001). Thus, elevated LDL is an indication for aggressive 
treatment for primary prevention of CVD.  
High Density Lipoprotein (HDL) as Risk for CVD 
 Desired levels of HDL cholesterol in men are >40 mg/dL and in women are >50 
mg/dL (CDC, 2017). HDL, often referred to as the good cholesterol, is considered an 
independent risk (protective) factor for CVD (Toth, 2004).  It is responsible for 
transporting excess fat and cholesterol and has anti-inflammatory properties reducing 
endothelial cell changes and decreases platelet aggregation.  Low levels of high-density 
lipoprotein cholesterol (HDL; <40 mg/dL) are associated with increased risk of 
cardiovascular events (Toth, 2004). The cardioprotective functions of HDL include 
antioxidative, anti-inflammatory, anti-apoptotic, anti-thrombotic, vasodilatory, anti-
infectious and antidiabetic activities (Hagstrom et al., 2016). The TRILOGY Acute 
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Coronary Syndrome trial evaluated HDL level as a dichotomous variable-very low 
(<30 mg/dL) vs, higher (≥30 mg/dL) and reported similar rate for a composite endpoint 
with essentially no risk difference between groups HR 1.13, 95%  CI [0.95, 1.34] for MI 
and stroke. However, risks for cardiovascular death HR 1.42, 95% CI [1.13, 1.78] and 
all-cause death HR 1.36, 95% CI [1.11, 1.67] were higher in patients with very low 
baseline HDL (Hagstrom et al., 2016).  
Low-Density Lipoprotein (LDL) as Risk for CVD       
 
Elevated LDL is an indication for primary prevention of CVD.  The rationale for 
activities focused on LDL reduction is based upon epidemiologic data documenting a 
continuous, positive, graded relationship between LDL concentration and CVD events 
and mortality (Leef, Bluementhel, & Martin, 2018; Wallis et al. 2000). Earlier evidence 
from The Framingham Heart Study demonstrated that men and women were >1.5 times 
more likely to develop clinically significant coronary artery disease if their LDL was 
>160 mg/dL compared to a reference population with LDL <130 mg/dL (Wilson et al., 
1998). Similarly, in the Atherosclerosis Risk in Communities (ARIC) study, the risk of an 
incident coronary heart disease event was elevated by approximately 40% for every 
39 mg/dL incremental increase in LDL (Sharrett et al., 2001). 
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Non-Traditional Risks For CVD 
 Depressive symptoms as a Risk for CVD 
 Major depression and depressive symptoms are commonly underdiagnosed and 
undertreated in patients with CVD (Celano & Huffman, 2011). Studies have found 
depression and its associated symptoms to be major risk factors for both the 
development of CVD and increased mortality post myocardial infarction (Silverman, 
Herzog, & Silverman, 2018). Furthermore when cardiac disease and major depression 
present together, the prognosis is worse (Celano & Huffman, 2011; Mehta et al., 2016)  
 The Enhancing Recovery in Coronary Heart Disease (ENRICHD) trial among 
patients who had recently suffered a myocardial infarction (MI), reported a diagnosis of 
depressive symptoms in 74% of the cohort (Carney et al., 2004).  Depressive symptoms 
were associated with an  included increased risk of CVD mortality HR of 1.57, 95% CI 
[1.06, 2.33], p=0.03  in a cross-sectional survey of 1,569 subjects (Ivanovs et al., 2018). 
Likewise, depressive symptoms evaluated among 1,928 persons with known coronary 
artery disease had an alarming effect.  Depressive symptoms were measured by the 
Depression Scale (DEPS), a 10 item self-rating depression scale. Those in the highest 
quartile of depression at baseline were 4 times at risk for cardiac related death 
compared to those in the lowest group, HR 4.0, 95% CI [1.5, 10.5], p< 0.0001. The third 
highest quartile was also significantly elevated compared to the lowest HR 2.3, 95% CI 
[1.3,  4.1], p <0.05. This study concluded that depression had a significant effect on 
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cardiac related deaths, but not deaths unrelated to cardiac disease (Lahtind et al., 
2018).  
 Findings from the Maine-Syracuse Study, (N=970) persons were measured for 
depressive symptoms using both the CES-D and the Zung self-rating depression scale 
(Crichton, Elias, & Robbins, 2016).  Significant findings included an association between 
risk for metabolic syndrome and CES-D, OR 1.79; p=1.79 and the Zung depression 
score OR 1.71; p<0.01. Alarming was the use of antidepressants which seemed to 
increase the risk of Met S compared to persons not taking antidepressants OR 2.22; 
p<0.001 (Crichton et al., 2016).  On the other hand, a smaller study conducted in 
Singapore included adults aged 21-50 years with major depression presently on 
antidepressant medications compared to non-depressed controls and non-medicated 
persons with depression (Ho et al., 2018). Persons taking antidepressants had 
significantly higher elevated blood pressure, elevated IL-6 and lower HDL, when 
compared to the non-depressed control group.  Researchers suggested screening for 
depression severity be added to the Framingham equation so not to miss major risks for 
developing CVD (Ho et al., 2018). This study did not identify a benefit to medications 
nor identify the medications used to treat depression.  They reported an interaction 
between TRIG and severity of depression.   
 Although evidence has strongly indicated that depression and/or depressive 
symptoms may significantly affect the risk of CVD, the effect may differ within different 
populations. Rates of depression are nearly twice as high in women compared to men 
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(Vaccarino & Bremner, 2016; WHO, 2017, CDC, 2012). Women diagnosed with 
depression have a higher incidence of cardiovascular disease (Lichtman et al., 2008; 
Mehta et al., 2016), and poorer outcomes post cardiac event, including higher rates of 
death over those without depressive symptoms (Celano & Huffman, 2011; Mehta et al., 
2016; Rutledge et al., 2006). A large study, (N=13,000) examined participants over a 2-
year span for effects of depression, measured with Beck’s Depression Inventory, and 
the risk for CVD. Those with depression were at 2 times higher risk for CVD; Men 
(n=6392), OR 2.14, CI 1.78, 2.56]; and women, (n=7153), OR 2.03, 95% CI [1.70, 2.43] 
(Piwonski, Piwonska, & Sygnowska, 2014).  
 Depression may affect different age groups differently. A Swedish study included 
people aged 25 to 64 with the diagnosis of depression, and those 25 to 79 hospitalized 
with nonfatal CVD (n = 1,767).  The results indicated a strong association between 
depression and CVD, and those diagnosed with depression under the age of 40 were at 
twice the risk for CVD compared to the older ages RR 2.17, 95% [CI 1.5, 3.03]. Those 
over the age of 70 years at the onset of depressive symptoms experienced no 
significant risk for CVD (Sundquist, Li, Johansson, & Sundquist, 2005).  
 Collectively, the evidence indicates that depression and/or depressive symptoms 
are a strong risk factors for CVD across various populations.  Depression can lead to 
unhealthy eating habits, poor sleep quality, a decrease in physical activity, and elevated 
inflammation, all of which may lead to atherosclerosis (Stapelberg, Neumann, Shum, 
McConnell, & Hamilton-Craig, 2011).  
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 Inflammation and Inflammatory Markers as Risk for CVD  
 Aging is associated with dysregulated immune and inflammatory responses. 
Inflammation has been suggested to be one of the mechanisms underlying the 
pathogenesis of several age-associated diseases disease including CVD (Libby, 2006) 
and obesity and diabetes (Shoelson, Herrero, & Naaz, 2007). 
 Age related effects of inflammation include overall low-grade inflammation due to 
cumulative tendencies.  The stress that an individual has experienced throughout life 
builds up and scars generating more inflammation.  It is thought that healthy persons 
may experience some of these aging changes as early as age 55 years (Lopez-
Candales, Hernandez-Bergos, Hernandez-Suarez & Harris, 2017). Chronic 
inflammation increases the risk for developing atherosclerosis, Alzheimer’s disease, and 
insulin resistance (Barzilai, Huffman, Muzumdar, & Bartke, 2012).  
 Gender differences were reported in a small pilot study seeking to evaluate 
gender differences in persons experiencing an acute myocardial infarction (AMI).  
Results found levels of IL-6 to be elevated significantly in men versus females. Patients 
were tested after hospitalization on day 3 post diagnosis of a NSTEMI and on day 5 
post diagnosis of a STEMI.  This study concluded a significant association between 
inflammatory markers IL-6 and CRP in men more so than women with a MI (Siennicka 
et al., 2018). The English Longitudinal Study of Ageing Study sought to evaluate the 
combined effect of both inflammation and depression. In men, the effect was highly 
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significant HR 3.89, 95% CI [2.04, 7.44]; p= 0.001 while in women a significant risk was 
not reported. Men with elevated inflammation and normal levels of symptoms of 
depression had elevated risk HR 2.43, 95% CI [1.59, 3.71]; p<0.001, whereas women 
were not at significantly higher risk HR  0.92, 96% CI [0.59, 1.44]; p=0.715 (Lawes, 
Demakakos, Steptoe, Lewis, & Carvalho, 2018). 
The inflammatory processes described within effects of diabetes and smoking 
illustrate some of the physiological changes that occur when exposed to an 
inflammatory process.  Normal inflammatory marker levels can be valuable in ruling out 
disease conditions. Conversely, an elevated inflammatory marker may indicate a higher 
probability of a condition being present or identifies the risk of being exposed to a 
specific disease condition. Various measures of inflammatory markers have been 
associated with higher risk of CVD (i.e. High sensitive C-reactive protein (hsCRP) and 
IL-6) being the most commonly reported (Chuang, Chih-Hung & Fang, 2014).  
 Inflammatory markers such as IL-6 and CRP have both been predictive of 
cardiac events. A prospective study over a six-year span followed over 900 male 
physician participants with no history of CVD. At the end of the study, 202 participants 
had experienced a myocardial infarction.  Participants with IL-6 levels in the highest 
quartile had a 38% higher risk compared to those in the lower range, with a relative 
index of 2.3 times that of those in the lower quartile (Ridker, Rifaai, Stampfer & 
Hennekens, 2000). Similar findings were seen in a Japanese study (N =121) in which 
fifty percent of the participants experienced a new cardiac event within a three-year 
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span. In this study, baseline IL-6 was found to be an independent predictor of MACE 
with those in the highest quartile of IL-6 compared to those in the lowest quartile HR 
3.33, 95% CI [1.63, 6.81] (Nishida et al., 2011). In this study after controlling for other 
variables, IL-6 was the better predictor of CVD, as hsCRP was not predictive (Nishida et 
al., 2011). Likewise, hsCRP and IL-6 were associated with CVD mortality and all-cause 
mortality, HR 2.15 and HR  2.11 respectively in the STABILITY study.  However, after 
adjustments Il-6 remained the stronger predictor and hsCRP was no longer significant 
(Held et al., 2017).  
 IL-6 has also been shown to be an independent predictor of CVD mortality after 
MI. Specifically, when IL-6 was measured 6 hours after first symptoms of an MI and 
patients were followed for 3 years to monitor mortality, those who had the highest 
reading of IL-6 had the highest mortality  and cardiac events, as indicated by Kaplan–
Meier plots (X2 14.13, p=0.0002) (Fan et al., 2011). This study recommended the 
possibility of treating with inflammation with medications such as tocilizumab to reduce 
the levels of IL-6 and to prevent atherosclerosis (Fan et al., 2011). 
 Evidence in recent years has demonstrated an association between elevated 
inflammatory markers and increased risk for CVD and mortality (Held et al., 2017; 
Nishida et al., 2011).   Although the etiology of the inflammation may vary greatly, early 
detection and identification may allow for treatment or interventions to reduce the 
inflammation and thus potentially reduce risk of CVD. 
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 Strong relationships seem prevalent among depression, CVD, and inflammation. 
Studies are mixed whether the relationships may be bidirectional.  What comes first 
inflammation or depression, CVD, or depression?  A meta-analysis by Howren, Lamkin 
and Suls (2009) suggested a positive association between depression and inflammation 
among patients with cardiac disease.  Elevated inflammatory markers have been shown 
to be predictors of heart disease and have been linked to both CVD and depression 
(Danesh, et al., 2004; Dixon et al. 2008; Empana et al., 2005; Manev et al., 2008; 
Taylor, Aizenstein & Alexopoulos, 2013).  A direct causal path from depression and 
CVD has been suggested after adjusting for inflammatory markers (Empana et al., 
2005).  A Malaysian study conducted among more than 400 persons noted bidirectional 
effects between depression and CVD. Depressive symptoms increased inflammatory 
markers leading to CVD, and an increased rate of CVD led to increased depression 
(Tajfard et al., 2014).  
 The joint effect of depression and/or depressive symptoms, inflammation and 
CVD have been reported in a number of studies. Men with both elevated C-Reactive 
Protein (CRP) with the presence of depressive symptoms had an increased risk of CVD 
related death HR 3.89, 95% CI [2.04, 7.44] (Lawes et al., 2018), whereas those with 
normal CRP and depressive symptoms had no significant increased risk for CVD (HR 
1.50, 95% CI [0.63, 3.6]; p= 3.61 (Lawes et al., 2018).  An Iranian study conducted on 
more than 462 persons also noted significant associations between depressive 
symptoms and inflammatory markers IL-6, IL-8 (p <0.05) and depressive symptoms. 
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These researchers concluded an interaction between depressive symptoms and CVD 
that was probably mediated by the inflammatory processes (Tajfard et al., 2014).  
 Sleep Quality/ Insomnia as Risk for CVD 
  Previous research suggests that poor sleep quality, sleep disorders, and 
insomnia increase the risk for CVD (Covassin & Singh, 2016). Key search words 
included sleep, insomnia, sleep disorders, hypertension, diabetes, obesity, heart 
disease, cholesterol, age, race, and gender Sleep is a potentially modifiable risk factor 
in the fight against CVD. Sleep quality has been associated with increased risk of many 
health conditions including CVD (Covassin & Singh, 2016).   Although, sleep quality 
may vary among individuals, the duration of sleep, time taken to fall asleep, one’s ability 
to stay asleep and daytime sleepiness or inability to stay awake have been significantly 
associated with the risk for CVD (Hoevenaar-Blom, Spijkerman, Kromhout, van den 
Berg, & Verschuren, 2011). Therefore, a review of current studies on sleep and CVD 
risk was conducted to shed light on the connection.    
 Changes in sleep patterns are common complaints in older people.  Age related 
differences include sleep that is less consolidated, with increased interruptions.  Change 
in sleep cycles including the Rapid eye movement (REM) cycle occurs earlier in sleep 
cycles compared to younger persons. There is evidence supporting that for every 
decade of an age they lose about 10-minutes of sleep. (Edwards, O’Driscoll, Ali, Jordan, 
Trinder & Malhotra, 2010). Aging is characterized by changes in both sleep and 
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circadian rhythms. Many older adults find their circadian rhythm has been moved 
forward.  Changes in body temperature and hormonal secretions regulated by the 
circadian rhythm such as melatonin and morning rise of cortisol seems to come at an 
earlier time.  Older persons tend to rise earlier than their younger counterparts (Dijk et 
al., 2000).  Although occasional sleep complaints may not be associated with age, older 
adults experience chronic sleep difficulties more often than by younger adults. A similar 
poll of 1500 older Americans (aged 55+) found that 67% reported trouble sleeping and 
that only one in eight had discussed these problems with their physicians (Lamberg, 
2003). It would be fair to say that older persons are at a greater risk for health-related 
problems for which may affect sleep (Edwards et al., 2010)  
 Sleep complaints may also vary within different races.   Results from the Multi-
Ethnic Study of Atherosclerosis (MESA) have Black men sleeping the shortest duration, 
and White women the longest. Black men complain of daytime sleepiness the most.  
None of the differences however were significant (Chen et al., 2015)  
 Cardiovascular disease may be affected by sleep quality in a number of ways. A 
study with over 20,000 participants found those with shortened sleep of less than six 
hours had a slightly higher risk of developing coronary vascular disease after controlling 
for relevant lifestyle factors such as smoking, exercise, and alcohol consumption HR 
1.23, 95% CI [1.04, 1.45].  Also, this study reported that the risk for CVD decreased with 
longer sleep, eight hours HR 0.87,  95% CI [0.74, 1.02] and for those with more than 
nine hours of sleep HR 0.77, 95% CI [0.58,1.02] (Hoevenaar-Blom, Spijkerman, 
Kromhout, van den Berg, & Verschuren, 2011). Sleep quality measured with a single 
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question (Do you usually rise feeling rested?)   combined with short duration of sleep 
demonstrated a significant increase in CVD risk for CVD HR 1.79, 95% CI [1.24, 2.58]; 
p<.05 (Hoevenaar-Blom et al., 2011).  
 The above evidence was supported in The Women’s Health Initiative 
Observational Study Participants (N=86,329) of female participants, aged 50 to 79. This 
study results found those with elevated insomnia scores had and elevated risk for CVD 
(38%).  Upon evaluating duration those with less than five hours and more than ten 
hours of sleep to have an increased risk for CVD with age and race adjusted models 
however in fully adjusted models, no statistical significance for less than 5 hours of 
sleep was appreciated (Sands-Lincoln et al., 2013).  However, upon testing for 
interaction, those with both insomnia symptoms and longer sleep duration, slept greater 
than 10 hours had nearly double the risk for CVD, HR 1.93, 95% CI [1.06, 3.51]; p<0.1 
(Sands-Lincoln et al., 2012). These results support the thought that quality of sleep 
influences the risk for CVD, increasingly so when duration and insomnia symptoms of 
bother, are both present.  
 Sleep quality can be affected by depression and or depressive symptoms.  
Persons with poor sleep quality were nearly 10 times more likely to have depression 
compared to those without symptoms in a community-based sample of 772 participants 
(Taylor, Lichstein, Durrence, Reidel & Bush, 2005).  Sleep quality, measured by 
Pittsburgh Sleep Quality Index (PSQI), and depression and anxiety, measured by the 
Hospital Anxiety and Depression Scale (HADS) were measured on patients hospitalized 
    
46 
 
with a variety of cardiovascular related diseased (N=1071). Among patients hospitalized 
with a cardiac event, 43% percent of patients reported poor sleep quality. Sleep quality 
after adjustments for covariates was a significant risk factor for depression in this group 
HR 1.09, 95% CI [1.03, 1.15]; p=0.002 (Matsuda et al, 2017).  Additionally, a test for 
interaction by gender, sleep and depression revealed differences among gender, 
women with poor sleep quality where at a much higher risk for depression compared to 
men; women OR 1.34, 95% CI [1.22, 1.48]; p<0.001, Men OR 1.17, 95% CI [1.12, 1.23]; 
p=0.017 interaction (p=0.008) (Matsuda et al., 2017). 
 There have been significant associations reported between increased 
inflammatory markers and sleep quality.  Those with interrupted sleep or sleep of 
extremely short or long duration have been associated with increased levels of CRP 
and IL-6 (Mullington, Simpson Meier-Ewert & Haak, 2010). Shift workers, those with 
circadian rhythm disorders, and those with reported shortened sleep or poor sleep 
quality, have also been identified as having elevated markers (Kudielka, Buchtal, Uhde 
& Wust, 2007; Patel et al., 2009).  Furthermore, insomnia appears to be associated with 
hypercortisolemia and a daytime shift of IL-6 and TNFα secretory patterns, conditions 
that may lead to multiple health problems including visceral obesity, insulin resistance, 
hypertension, and osteoporosis that, in turn, may affect longevity (Vgontzas et 
al., 2003). Smoking has been associated with sleep quality. Common reported 
difficulties in smokers include, sleep latency, duration with frequent awakening daytime 
sleepiness (Wetter & Young, 1994). 
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Summary 
 Current evidence suggests the modifiable risk factors depression and or 
depressive symptoms, inflammation, and quality of sleep, play a role in the development 
of CVD. Studies collectively have found depression and or depressive symptoms to 
increase one’s risk for CVD by approximately 1.5 times or more.  The exact link as to 
how depression would increase a person’s risk is not fully known and may be the effect 
of many components.  Depression and or depressive symptoms effects an individuals’ 
diet, activity, sleep patterns and may also result in an inflammatory response.  The link 
from inflammation and CVD is strong and may be related to the direct impact on 
atherosclerosis, increased blood pressure as well as link to diabetes. However, the 
direct causes of increased inflammation are multiplicative.  Among the inflammatory 
markers frequently used in predicting CVD, IL-6, CPR and hsCRP were reported to be 
most predictive of CVD.  Though evidence supports an association between sleep and 
CVD risk, Sleep quality is not a consistent predictor of CVD. Furthermore, the etiology 
of sleep difficulties is not always clear. 
 Despite evidence supporting the influence of depression, inflammation and sleep 
on CVD, uncertainties remain.  Therefore, supporting, this secondary analysis of the 
data from The Heart Strategies Concentrating on Risk Evaluation study to evaluate the 
predictive effect of depressive symptoms, inflammation, and sleep quality on the risk for 
developing a major adverse cardiac event.   
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CHAPTER THREE:  
METHODS 
 Chapter III presents the study design, rationale, sample and setting, and measures 
utilized from the Heart Strategies Concentrating on Risk Stratification study (Heart 
SCORE). This chapter also provides the aims and rationale of this secondary analysis. 
The analytic plan includes the specific variables that were considered, and methods 
used for statistical analyses of the data.  
Study Design 
 This study is a secondary analysis of the data obtained from the Heart Strategies 
Concentrating on Risk Evaluation (Heart SCORE), a longitudinal prospective cohort 
study conducted over a 14-year period. The ongoing Heart SCORE study has been 
prospectively examining cardiovascular disease (CVD) risk factors and CVD events on 
an initial cohort of 2,000 enrolled adults ages 45 to 75 at study entry. The data collection 
was started in 2003 is still active with data obtained up to November 2017 for this 
analysis (Bambs et al.,2011).  The current study explores the predictive relationship 
between the modifiable risk factors, depressive symptoms, inflammation, and quality of 
sleep, on the risk of developing cardiovascular disease. 
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Sample and Setting 
As referenced above, the Heart SCORE study includes 2000 adults ranging from 
the ages of 45 to 75 years, who were living within the greater Pittsburgh, Pennsylvania 
area at the time of enrollment. The original aims of the study were to improve risk 
stratification and identify racial disparities within a population (Bambs et al., 2011).  To 
meet the aims of the study, a priority was placed on oversampling of minorities to 
include approximately equal representation of White and Black subjects to permit 
stratified analyses by race in relation to risk of CVD.  The specific target recruitment 
goals included 2,000 participants, 50% Black, 1,000 participants with low CVD risk, as 
measured by the Framingham risk score, 1,000 with intermediate or elevated risk, and 
200 with established CVD.  Recruitment strategies included mailings, referrals, and 
advertisements. To meet approximate proportional representation from Black 
communities, local organizations and church groups were targeted (Bambs et al., 2011). 
Rationale for the Primary Study 
 The Heart SCORE study was designed with the aim of improving risk 
stratification, including identification of mechanisms associated with racial disparities for 
population differences in CVD (Bambs et al, 2011).  To achieve this goal, after a 
baseline evaluation, subjects underwent annual visits which included measurements of 
traditional and emerging CVD risk factors, tabulation of adverse events and 
assessments of subclinical atherosclerosis. 
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Rationale for Secondary Analysis 
This secondary data analysis sought to make use of this large longitudinal study 
to investigate the extent to which depressive symptoms, inflammation, and sleep quality 
are independently associated with risk of experiencing a major adverse cardiac event. 
To meaningfully lower the incidence of CVD and decrease mortality and disability, it is 
imperative to identify potentially modifiable risk factors. Depressive symptoms, 
inflammation, and sleep quality have been mentioned in numerous studies as having 
potential predictive value for risk of development of CVD. These suggested 
relationships provided the rationale for examination of the Heart SCORE data, a large 
community-based cohort study with long-term follow-up.   
Protection of Human Subjects 
The University of Pittsburgh Institutional Review Board (IRB) approved the Heart 
SCORE study to ensure that the privacy and rights of the participants were protected. 
Participants in the Heart SCORE study were informed of any risks including the time 
commitment for the longitudinal data collection. Written informed consent was obtained 
from all participants. All data obtained was de-identified before transfer for analysis.  
Approval from the Institutional Review Board at the University of South Florida was 
obtained (Appendix A).  
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Exclusion Criteria of the Heart SCORE Study 
The Heart SCORE study excluded persons with major comorbidities, those in 
poor health, or those with life expectancies less than five years.  Additionally, 
participants had to agree to participate in annual follow up exams.  Those with previous 
major cardiac events could be enrolled into the study. 
Exclusion Criteria for Secondary Analysis 
 This secondary analysis excluded study subjects with a history of major adverse 
cardiac event (MACE) prior to the baseline data collection.  This included myocardial 
infarction, cerebrovascular accident, or coronary revascularization. Additionally, persons 
with missing outcome data were excluded. The original study collected data on 2,000 
persons, of which, 105 were eliminated under the exclusion criteria for this secondary 
analysis, resulting in a final N=1895.   
Outcome Variables of the Current Secondary Analysis  
 The present analysis defined CVD and cardiovascular events as Major Adverse 
Cardiovascular Events (MACE) using two closely related definitions.  
 Major Adverse Cardiac Event (MACE1) was defined as a diagnosis of at least one 
of the following; cerebral vascular accident, acute ischemic syndrome, myocardial 
infarction, coronary revascularization procedure, or experiencing cardiac death during 
the duration of the study.   
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 Major Adverse Cardiac Event (MACE6) was defined as diagnosis of one of the 
following; cerebral vascular accident, acute ischemic syndrome, myocardial infarction, 
or death from any cause during the duration of the study.   
Predictor Variables of the Current Secondary Analysis 
 Depressive Symptoms/ CES-D Scale 
 The Heart SCORE study recognized the contribution of psychosocial health to 
the physiological development of CVD. In this regard, the Center for Epidemiologic 
Studies-Depression Scale (CES-D) was used as a measure of depressive symptoms.  
The CES-D is a highly reliable tool with good reported internal consistency (alpha 
coefficient of >0.85) designed to identify depressive symptoms rather than to diagnose 
depression (Fischer, 2009; Smarr & Keefer, 2011). The items are scored on a scale of 
0-3, with 0 indicating no symptoms and a 3 representing a greater severity of 
symptoms. Traditionally, a score of 16 or higher is consistent with a diagnosis of 
depression (Radloff, 1977). The total CES-D score can range from 0-60. Within Heart 
SCORE, total scores ranged from 0-51, with a mean of 7, and 10 was at the 75th 
percentile. Only 12% of the respondents had a value of 16 or greater at baseline. For 
the present analysis, the data was divided into tertiles consisting of 3 groups of equal 
participants, based on ranked values of the CES-D score and were coded as follows: 
Group 0 (CES-D, 0-4); Group 1 (CES-D > 4-9); Group 2 (CES-D > 9).    
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Inflammation/IL-6 
 The inflammatory response has been associated with multiple aspects of CVD, 
most importantly atherosclerosis.  The Heart SCORE study included several measures 
of inflammatory biomarkers. Biomarkers that are frequently studied and associated with 
CVD include both C-reactive protein (CRP) and interleukin-6 (IL-6).  These markers are 
associated with an acute phase stress reaction and systemic inflammation and have 
shown consistent independent relationships with CVD (Langenberg, Bergstrom, 
Scheidt-Nave, Pfeilschifter, & Barrett-Conner, 2006; Pearson et al., 2003).  
 In Heart SCORE, both, CRP and IL-6 were measured fasting with a venous 
blood draw using standard laboratory technique at the University of Pittsburg Medical 
Center clinical laboratory, at baseline. IL-6, with CRP measured as milligrams per 
deciliter (mg/dL) and IL-6 measured as picograms per milliliter (pg/ml) (Bambs et al., 
2011). Due to high correlation of these measures, IL-6 was selected as the primary 
measure of inflammation. Results of IL-6 were highly skewed to the right, ranging from 
(0.038 to 48.27 pg/ml). Therefore, a natural log transformation was also considered.  
The median IL-6 value was 1.708 with 95% of participants having a value less than 5.7 
pg/ml.  A plot of frequency of MACE6 by half unit of IL-6 seemed to show a continual 
increase of events from 0 until about 2 pg/ml (the 60th -70th percentiles), and then a 
leveling off until passing the 95th percentile.  
 Hence, for ease of interpretation, the data was divided into tertiles, containing 
equal number of participants based on ranked values of IL-6.  Tertile cut-points were 
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(1.245 pg/ml and 2.28 pg/ml).  Initial models indicated the risk of MACE (either 1 or 6) 
was similar for the second and third tertiles of IL-6. Therefore, the later tertiles were 
combined. Thus, IL-6 was treated as a dichotomous variable with the cut point at the 
33.3rd percentile (1.245 pg/ml).   
 Sleep Quality / Insomnia Scale 
Sleep quality was measured by The Insomnia Symptom Questionnaire (ISQ). 
This included assessment of symptoms of insomnia experienced over the last month as 
an overall measure of sleep quality. This 13-question self-report survey is widely used 
to assess for sleep disorders and reportedly has a high Cronbach-α coefficient of 0.89 
indicating good internal consistency (Okun et el., 2009).  The proposed algorithm for 
scoring the scale and identifying someone as having insomnia is as follows.  (1) The 
participant indicates trouble falling asleep, trouble waking during the night or sleep that 
is unrefreshing (items 1, 2 or 5) frequently or always; (2) The participant has the 
problem(s) indicated in (1) for 4 weeks or longer and (3) the participant indicates that 
s/he has one or more daytime sequelae (items 6-13), “quite a bit,” or “always” (Okun et 
al., 2009).  
Within Heart SCORE, this tool was administered as a self-report and many 
participants who indicated symptoms of insomnia did not answer the questions about 
duration. Consequently, three new categories for sleep quality were defined: (1) 
Participants who did not indicate difficulty falling asleep, difficulty staying asleep, or 
sleep that is unrefreshing as frequently or always: (items 1, 2 or 5); (2) Participants who 
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did indicate trouble falling asleep, trouble waking during the night, or sleep that is 
unrefreshing as frequently or always, (items 1, 2 or 5)  but did not select  “quite a bit” or 
“always” for any daytime sequelae; and (3) Participants who indicated trouble falling 
asleep, trouble waking during the night or sleep that is unrefreshing as frequently or 
always, and reported having one or more daytime sequelae (items 6-13), as “quite a 
bit,” or “always”. 
Covariates 
 Demographics  
 Age, gender, and race were included as covariates in every model.  Race 
included White, Black, and Other.  Less than 4% of respondents self-classified 
themselves as other.  Statistical analysis of this population proved difficult and is often 
marked non-determinant in tables or excluded from statistical analysis.  
 Smoking 
   Subjects were asked about smoking history. Self-reported use of cigarettes was 
categorized as; current, former, and never a smoker. Smoking history was included in 
all models as a categorical variable with two indicator variables representing current or 
former smoker. The number of cigarettes smoked per day, number of years smoked, 
and the number of years since quitting smoking were not available for analysis. 
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 Diabetes Mellitus 
  During the baseline screening process, subjects were asked to complete self-
report questionnaires.  The questionnaire included a self-report of having diabetes, yes 
or no?  Are you being treated for diabetes, yes or no?  Diabetes was entered all models 
as a dichotomous variable.  
 Glucose 
 Baseline fasting venous glucose level, with standard analytical techniques were 
entered as a continuous variable (Bambs et al., 2011).    
 Use of Antihypertensive Medications 
 Subjects were asked if diagnosed with hypertension, yes or no, and are you 
currently taking medications for hypertension yes or no?  Use of antihypertensive 
medications was entered as a dichotomous variable.  
 Systolic Blood Pressure (SBP) 
 Systolic blood pressure was included as a continuous variable for analysis. Blood 
pressures were obtained following the AHA gold standard within the Heart SCORE 
study.  Subjects were seated, with legs uncrossed for a minimum of 5 minutes prior to 
taking the blood pressure. Experienced nurses using a manual sphygmomanometer 
took the blood pressures. The blood pressures were taken with the appropriated sized 
cuff and recorded twice, with a resting five minutes between readings.  The average of 
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the two readings was recorded as the sample blood pressure. Equipment was subject to 
routine calibration and was replaced when reliable performance was not assured 
(ACC/AHA, 2017, Bambs et al., 2011).     
 Obesity 
 The Heart (SCORE) study included measures for BMI, skin fold tests, waist 
circumference and waist to hip ratio.  The present analysis included continuous 
measures of BMI (kg/m2) and waist circumference in centimeters as covariates.  
  Cholesterol  
  High-density lipoprotein (HDL). was included in the initial models.  
  Triglycerides (TRIG). was included in initial models. 
  Statin Medications as determined from the question: Are you 
presently taking a “statin” medication? Yes or No, by a self-report questionnaire,  
  The laboratory lipid panel was obtained while participants were fasting for no less 
than six hours and after resting for a period no less than fifteen minutes prior to blood 
draw.  The initial baseline lab studies of high-density lipoprotein (HDL), triglycerides 
(TRIG), and low-density lipoprotein (LDL) were measured using standard laboratory 
procedures.  Follow up testing was completed using the Vertical Auto Profile test (VAP) 
method. These 3 lipid measures were included in initial models and entered as 
continuous measures.  In addition, patients were asked if they were presently taking a 
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lipid lowering medication classified as a “statin’ medication? This was included as a 
dichotomous measure as a covariate 
Statistical Analysis 
 The statistical analysis was guided by the aims of the study; 
 Aim 1 
 To prospectively evaluate the independent relationships between traditional 
cardiac risk factors, depressive symptoms, inflammation, and sleep quality, on long-
term risk of MACE1 and MACE6. 
 Initially, univariate analysis of traditional risk factors for CVD were examined for 
association with MACE1 and MACE6 by use of Cox proportional hazards regression.  
This approach led to the selection of a final set of traditional risk factors to be included 
in all models. The variables that were screened included BMI, waist circumference, 
diabetes mellitus, systolic BP and use of hypertensive medications, HDL, TRIG, use of 
lipid-lowering agents, and glucose.  Through stepwise selection, a variable was retained 
for future models based on the Wald Chi-Squared test, and the association with either 
MACE1 or MACE6 with selection p-values set at 0.2.  The Wald Chi-Squared Test is 
used to test the null hypothesis that the effect from the predictor variable is 0.  A 
significant p-value from a Wald Chi-Squared Test rejects the null, indicating a significant 
effect of the variable on the outcome of interest (Tabachnick, & Fidell, 2007).  Retained 
    
59 
 
variables are subsequently indicated in Table 2, ad race was included in all models 
irrespective of statistical significance due to presumed biological relevance.   
Once the set of traditional risk factors was identified, separate Cox Proportional 
hazard models were fit adding in (separate models) the three novel risk factors of 
interest: depressive symptoms, IL-6, and insomnia.  The use of Cox proportional 
hazards regression was chosen because it can accommodate both continuous and 
categorical predictor variables and is able to provide individual effects known as hazard 
ratios (HR) for multiple predictors simultaneously. However, with the use of this method, 
there are a few assumptions that must be considered (Tabachnick, & Fidell, 2007).    
1.) Independence between individual subjects. 
2.) Multiplicative relationship between hazard and predictors. 
3.) The hazard ratio is constant (i.e. proportional) over the time tested.  
4.) The hazard ratio represents a 1 unit of change in risk of the outcome of 
interest holding all other predictors constant. 
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 Aim 2 
 To prospectively evaluate whether gender modifies the relationships between 
depressive symptoms, inflammation, and sleep quality on long-term risk of MACE. 
 To determine whether the effects of IL-6, depressive symptoms and insomnia in 
predicting MACE1 or MACE6 differed between males and females, three additional 
models were run: Interaction Models 1-3 included the interaction term(s) between 
gender with depressive symptoms, gender with IL-6 and gender by insomnia, 
respectively. P-values from the interaction terms were examined to evaluate potential 
effect modification. In addition, in stratified analyses, respective hazard ratios for 
depressive symptoms, IL-6, and insomnia were summarized for males and females, 
respectively. 
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CHAPTER FOUR: 
DATA ANALYSIS 
 This chapter provides a descriptive summary of the data obtained from the Heart 
Score Study and presents the data analysis based on the specific aims of this study.   
 The most recent follow-up data, including information on major cardiac events, 
was collected as of November of 2017 and covers a mean of 9.9 years.  Table 1. 
provides summary statistics on the participants and variables of interest in this study. 
Continuous variables are tested with student t-tests and presented as mean and 
standard deviation, while categorical variables are presented as frequencies and 
percentages and were analyzed with Chi-Square tests.  
Descriptive Statistics 
 The participants upon entrance into the study included 1,256 females (66%), 639 
males (34%), ranging from 45 to 75 years of age with a median age of 60 years. Race, 
provided by participants as a self-report, was nearly equally represented with Blacks 
42% (n=799), Whites 55% (n=1047), and Other 3% (n=49).  Participants were followed 
for the development of a major adverse cardiac event (MACE).  Six percent, (n =113) of 
the 1,895 participants experienced a cardiac event as defined by the MACE1 criteria.  
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Table 1. Descriptive Statistics of the Sample 
 MACE1 MACE6 
 Yes (n=113) 
No 
(n=1782) p-value Yes (n=160) 
No 
(n=1735) 
p-
value 
Age Mean/SD 62.81±7.42 58.63 ± 7.41 <0.001  63.23±- 7.46 58.47± 7.35 <0.001  
%Female 55 (48.67) 
1201 
(67.40) <0.001  76 (47.50) 
1180 
(68.01) <0.001  
Race   0.835   0.180 
   White 64 (56.64) 983 (55.16)  85 (53.13) 962 (55.45)  
   Black 47 (41.59) 752 (42.20)  74 (46.25) 725 (41.79)  
   Other 2 (1.77) 47 (2.64)  1 (0.63) 48 (2.77)  
BMI kg/m2   30.56±6.33  30.01±6.36  0.380  30.26± 6.51  30.02±6.35  0.656  
Waist (CM)  99.78±15.56  95.59±15.12  0.005   99.16±16.23  
95.54 
±15.04  0.005   
Smoking   0.216   0.001  
   Current smoker 15 (13.27) 177 (10.02)  29 (18.24) 163 (9.47)  
   Former smoker 52 (46.02) 730 (41.31)  67 (42.14) 715 (41.55)  
   Never smoker 46 (40.71) 860 (48.67)  63 (39.62) 843 (48.98)  
Diabetes Mellitus 24 (21.43) 157 (8.86) <0.001 29 (18.24) 152 (8.81) <0.001 
Systolic Blood 
Pressure (mmHg)  144.2±20.72  135.7±19.35  <0.001   142.8±20.08  135.6±19.37  <0.001  
BP meds 59 (52.21) 700 (39.39) 0.007  79 (49.38) 680 (39.31) 0.013 
HDL  53.44±13.00  57.99±15.00  0.002   55.18 ±14.86  57.94±14.91  0.027   
Triglycerides  
126.5 
±58.57  122.9±76.70  0.623  126.2± 80.34  122.8±75.31  0.596  
Statin meds 30 (26.55)  336 (18.91)  0.046  36 (22.50) 330 (19.08) 0.294 
Glucose  105.4±32.23  98.27±25.32  0.004   104.0 ±24.06  98.22±25.94  0.007   
IL-6   <0.001    <0.001  
Lowest tertile 17 (17.17) 568 (34.30)  27 (19.15) 558 (34.57)  
Upper two tertiles  82 (82.83)  
1088 
(65.70)   114 (80.85)  
1056 
(65.43)   
DEP S /CES-D 7.00± 7.62 6.84±7.98 0.838 7.04±7.23 6.84±8.03 0.744 
Dep S   0.791   0.274 
   Low CES-D 38 (33.63) 641 (36.42)  48 (30.38) 631 (36.79)  
   Mid CES-D 35 (30.97) 544 (30.91)  54 (34.18) 525 (30.61)  
   High CES_D 40 (35.40) 575 (32.67)  56 (35.44) 559 (32.59)  
Sleep Quality       
   Insomnia   0.981   0.688 
   None/low freq.  64 (64.54) 991 (60.57)  93 (63.70) 962 (60.35)  
   Hi freq./low day 22 (21.15) 356 (21.76)  28 (19.18) 350 (21.96)  
   Hi freq./hi day 18 (17.13) 289 (17.67)  25 (17.12) 282 (17.69)  
Ŧ insomnia complaints include Trouble falling asleep, trouble with waking during the night and unrefreshing sleep. For those with 
complaints, day time problems are assessed.   Note. ***, **, * denotes significant, p=<0.001, p<=0.01, p<=0.05, respectively. B 
denotes significance is borderline or close to significant, 0.05 =<p<0.1   Depressive symptoms (DEP S)  
    
63 
 
The rate of MACE1 was 9% for males, 4% for females, and by race, 6% for whites, 6% 
for blacks, and 4% for other. Nine percent, (n=160) of the 1,895 participants developed 
CVD as defined by MACE6. The rate of MACE was 13% for males, 6% for females, and 
by race, 8% for whites, 9% for blacks, and 2% for other. 
Analysis for AIM 1  
 Independent relationships between traditional predictor variables and the 
outcome variables of MACE are seen in Table 2, as determined by stepwise selection 
(Model 1 for MACE 1 and Model 2 for MACE 6). Thus, each model thereafter was 
adjusted for established cardiovascular risk factors consisting of gender, race, diabetes, 
smoking, systolic blood pressure, and HDL cholesterol.  Cox proportional hazard 
models were fit with the purpose of evaluating relationships between the above- 
 
 
 
 
 
 
 
Table 2. Stepwise Selection Traditional Risk factors 
 
 MACE1 Selected MACE6 
Parameter p-value  p-value 
N= 113 1782 160 
Age (years) <.0001 XXX <.0001 
Gender 0.028 XXX 0.0002 
Race 0.737 XXX 0.1286 
Diabetes 0.004 XXX 0.0018 
Smoking 0.148 XXX <0.0001 
Waist in (cm) 0.292  0.4247 
 BMI (kg/m2) 0.354  0.8124 
HDL mg/dL 0.077 XXX 0.6336 
Triglycerides (mg/dL) 0.289  0.4221 
Use of Statin med 0.673  0.918 
Systolic BP (mm Hg) 0.022 XXX 0.072 
Antihypertensive meds 0.750  0.669 
Glucose mg/dL 0.876  0.790 
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mentioned traditional risk factors, and then the novel risk factors of interest which 
included depressive symptoms, inflammation, and sleep quality. This approach was 
used for estimating long-term risk of either MACE1 or MACE6. These models are 
provided to illustrate the p-value criteria used for inclusion of covariates, realizing that 
race was included uniformly due to presumed biological importance.  The models 
provided the basis for subsequent entry of the novel predictors of interest to estimate 
the independent relationship with risk of MACE. 
Effect of Traditional Risk Factors for CVD 
 Table 3 shows the hazard ratios with 95% confidence intervals, for the traditional 
risk factors on developing MACE. As age increases by one year, the estimated adjusted 
higher risk for developing CVD was approximately 7% for MACE1 and 9% for MACE6.  
Males were at significantly higher risk of MACE with adjusted hazard ratios of 1.80 and 
2.20 for MACE1 and MACE 6, respectively (i.e. approximately 2-fold higher risk overall). 
Independent Effect of Diabetes and Traditional Risk for CVD 
 Having diabetes more than doubled the risk for the development of MACE for 
both MACE1, HR 2.34, 95% CI [1.46, 3.77], and MACE6 HR  2.10, 95% CI [1.37, 3.20] 
categories (see Table 3).  Race was not associated with risk of development of CVD 
within this population group.   
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Independent Effect of Smoking and Traditional Risk Factors for CVD  
The effect of being a smoker was highly significant (p<0.0001). Those who 
smoke were 1.8 times more likely to develop MACE1 than non-smokers and 2.6 times 
greater risk for developing CVD as defined by MACE6 see (Table 3). Persons reporting 
having been former smokers had risks near that of a nonsmoker with no significant 
increase in risk.    
 
 
 
Table 3. Effect of Traditional Risk Factors on Risk for CVD 
 MACE1 MACE6 
Parameter 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Age (years) 1.072 [1.043, 1.102] <.0001 1.089 [1.064, 1.115] <.0001 
Gender   0.003   <.0001 
   Female (Reference)  (Reference)  
   Male 1.804 [1.214, 2.681]  2.196 [1.565, 3.082]  
Race     
   White  (Reference)   (Reference)  
   Black 0.902 [0.601, 1.353]  1.224 [0.873, 1.717]  
   Other 0.568 [0.139, 2.328]  0.181 [0.025, 1.309]  
Diabetes 2.344 [1.459, 3.767] .0004 2.096 [1.372, 3.201] .0006 
 Smoking     
   Non- Smoked (Reference)   (Reference)  
   Current Smoker 1.813 [0.993, 3.309] 0.05 2.641 [1.645, 4.242] <.0001 
    Former Smoker 1.084 [0.722, 1.626]  0.937 [0.658, 1.334]  
High-Density 
Lipoprotein (mg/dL) 0.987 [0.972, 1.001] 0.07  
0.998 
[0.985, 1.009]  
Syst Blood Pressure 
(mm Hg) 1.013 [1.004, 1.023] 0.007 1.009 [1.001, 1.017] 0.03 
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Independent Effect of High-Density Lipoprotein (HDL) and Traditional  
Risk for CVD 
 HDL cholesterol was not associated with future risk of MACE1 or MACE yet was 
in the direction of higher values being associated with overall lower risk -- see Table 3.  
Independent Effect of Systolic Blood Pressure and Traditional Risk Factors on 
Risk for CVD.  
Higher systolic blood pressure was statistically associated with a higher risk of 
both MACE1 and MACE6 classifications of CVD. The hazard ratio represents a 1 unit of 
change (Tabachnick, & Fidell, 2007). By extension, a 10-mm Hg increase in systolic 
blood pressure increased the risk of MACE1 by approximately 13%.   
Independent Effect of Depressive Symptoms and Traditional Risk Factors on Risk 
of CVD 
 When adding the novel predictor of depressive symptoms (see Table 4) into the 
model with the traditional risk factors, there was evidence of mild to moderate increase 
in the risk of CVD. Specifically, the middle and higher tertiles of depressive symptoms 
suggested an increase in the risk of MACE1 by 21% and 43%, respectively. These did 
not achieve statistical significance. However, the middle and higher tertiles of 
depressive symptoms was statistically associated with a higher risk of MACE6 with 
adjusted hazard ratio estimates of 1.65 and 1.68, respectively.  
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Table 4. Traditional Risk Factors Adding Depressive Symptoms (CES-D) on 
MACE 
 MACE1 MACE6 
Parameter 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Age (years) 1.075 [1.046, 1.105] <0.0001 1.095 [1.069, 1.122] <.0001 
Gender        
   Female  (Reference)   (Reference)  
   Male 1.89 [1.264, 2.817] 0.0019 2.35 [1.665, 3.323] <.0001 
Race     
   White  (Reference)  (Reference)  
   Black 0.91 [0.607, 1.366]  1.219 [0.866, 1.715]  
   Other 
0.57 
[0.140, 2.343]  0.19 [0.026, 1.367]  
Diabetes 2.33 [1.452, 3.749] 0.0005 2.162 [1.415, 3.303] 0.0004 
Smoking      
   Non- Smoker  (Reference)   (Reference)  
   Current Smoker 1.72 [0.938, 3.148] 0.079 2.554 [1.582, 4.125]  
    Former Smoker 1.08 [0.722, 1.624]  0.935 [0.654, 1.335]  
High-Density Lipoprotein 
(mg/dL) 0.99 [0.973, 1.00] 0.082 
0.997 
[0.985, 1.009]  
Systolic Blood Pressure 
(mm Hg) 1.01 [1.003, 1.022] 0.010 1.009 [1.000, 1.017] 0.042 
DEP S / (CES-D)       
CES-D, Low (0-4) (Reference)  (Reference)  
CES-D, Mid (>4-9) 1.21 [0.757, 1.919] 0.430 1.648 [1.107, 2.454] 0.013 
CES-D, Higher (>9) 1.43 [0.906, 2.259] 0.124 1.678 [1.116, 2.522] 0.012 
Note. ***, **, * denotes significant, p=<0.001, p<=0.01, p<=0.05, respectively. B denotes significance is borderline or close to 
significant, 0.05 =<p<0.1   Depressive symptoms (DEP S)   
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Independent Effect of Inflammation and Traditional Risk Factors on Risk for CVD 
 When adding the novel predictor of IL-6, hazard ratio estimates for the traditional 
risk factors were only nominally attenuated. Specifically, age, gender, diabetes, 
smoking, and systolic BP all remained significant risk factors. Importantly, the effect of 
an elevated IL-6 on risk of developing CVD was substantial for both MACE1, HR  2.45, 
95% CI [1.41, 4.25]; p= 0.001 and MACE6 HR 2.1, 95% CI [1.36, 2.28]; p=<0.001 (see 
Table 5).  These results indicated that high inflammation is a strong, independent risk 
factor for long-term risk of MACE. 
 
Table 5. Traditional Risk Factors adding Inflammation (IL-6) on MACE 
 
 MACE1 MACE6 
Parameter 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Age (years)  1.077  [1.046, 1.109]  <.0001 1.090  [1.063, 1.117]  <.0001 
Gender   0.004   <.0001 
   Female  (Reference)   (Reference)  
   Male 1.85 [1.206, 2.844]  2.39 [1.666, 3.454]  
   White (Reference)  (Reference)  
   Black 0.815 [0.523, 1.270]  1.137 [0.790, 1.633]  
   Other 0.576 [0.140, 2.370]  0.181 [0.025, 1.309]  
Diabetes 1.931 [1.139, 3.274] 0.014 1.569 [0.973, 2.531] 0.064  
   Never Smoked (Reference)   (Reference)  
   Current Smoker 1.968 [1.067, 3.630] 0.030 2.629 [1.615, 4.282] 0.0001 
    Former Smoker 0.921 [0.593, 1.429]  0.834 [0.571, 1.218]  
High-Density 
Lipoprotein (mg/dL) 0.99 [0.975, 1.006] 
0.2220
. 
0.999 
[0.986, 1.012]  
Systolic Blood 
Pressure (mm Hg) 1.012 [1.001, 1.022] 
 
1.009 [1.001, 1.018] 0.039  
Inflammation   IL-6     
   IL-6 (pg/ml) (low)  (Reference)  (Reference)  
   IL-6 (pg/ml) (Higher) 2.445 [1.407, 4.248] 0.001 2.111 [1.357, 3.285] 0.0009  
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Independent Effect of Sleep Quality / Insomnia on Risk for CVD 
 The inclusion of mild or more severe insomnia was not statistically associated 
with risk of either MACE1 or MACE6 beyond the influence of traditional risk factors (see 
Table 6). 
Table 6. Traditional Risk Factors adding Sleep Quality (Insomnia) on MACE 
 MACE1 MACE6 
Parameter 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Age (years) 1.077 [1.046, 1.109] <.0001  1.093 [1.066, 1.121] <.0001 
Gender   0.001    <.0001  
    Female (Reference)  (Reference)  
    Male 1.998 [1.31, 3.021]  2.404 [1.686, 3.429]  
Diabetes 2.303 [1.396, 3.800] 0.001  2.202 [1.288, 3.173] 0.002  
 Smoking     
   Non- Smoker (Reference)  (Reference)  
   Current Smoker 2.136 [1.154, 3.953] 0.015  3.063 [1.838, 5.023] <.0001  
    Former Smoker 1.076 [0.702, 1.649]  0.971 [0.668, 1.410]  
High-Density 
Lipoprotein(mg/dL) 0.987 [0.972, 1.002] 0.08  
0.996 
[0.984, 1.009]  
Syst Blood Pressure (mm Hg) 1.010 [1.00, 1.021] 0.043  1.008 [0.999, 1.016] 0.091 
Sleep Quality- Measured by Insomnia Scale (IS)     
   IS (No symptoms)-1 (Reference)  (Reference)  
   IS (Mild) -2 1.031 [0.633, 1.677]  0.914 [0597, 1.400]  
   IS (Daytime bother)-3 1.197 [0.704, 2.038]  1.189 [0.751, 1.881]  
Note.  Ŧ Sleep Quality/insomnia complaints 1. include Trouble falling asleep, trouble with waking during the night and 
unrefreshing sleep. For those with complaints, day time problems are assessed.  Blood Pressure (BP) 
 
Collective Effect of Traditional and Novel Risk Factors 
 
 When both traditional and all three novel risk factors were considered, adjusted 
hazard ratios tended to be attenuated to a small extent (see Table 7). Nonetheless, with 
this full set of risk factors, older age, male gender, diabetes, current smoker, and high 
inflammation remained strong independent risk factors for both MACE1 and MACE6. 
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Depressive symptoms in the upper tertile indicated a higher adjusted risk for MACE6 
but not for MACE1. The estimated independent effect of high IL-6 was substantial with 
adjusted hazard ratios of 2.77 and 2.34 for MACE1 and MACE6, respectively 
 
 
Table 7.  Effect of Traditional Risk Factors adding, Depressive Symptoms, 
Inflammation and Sleep Quality 
 MACE1 MACE6 
Parameter 
Haza
rd 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Hazar
d 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Age (years) 1.087 [1.054, 1.122] <.0001 1.100 [1.070, 1.131] <.0001 
   Female (Reference)  (Reference)  
   Male 2.141 [1.36, 3.364] 0.001 2.799 [1.897, 4.131] 0.001 
   White (Reference)   (Reference)  
   Black 0.812 [0.513, 1.298]  1.111 [0.754, 1.637]  
   Other 0.337 [0.046, 2.45]  (Non-determinant)  
Diabetes 1.915 [1.101, 3.330] 0.021  1.558 [0.963, 2.59] 0.08  
  Never- Smoked (Reference)   (Reference)  
   Current Smoker 2.147 [1.138, 4.048] 0.018  2.849 [1.699, 4.777] <0.0001  
   Former Smoker 0.891 [0.562, 1.411]  0.855 [0.572, 1.278]  
HDL (mg/dL) 0.991 [0.975, 1.008]  01.00 [0.986, 1.014]  
Systolic BP (mm Hg) 1.008 [0.997, 1.019]  1.007 [0.998, 1.017]  
CES-D, Low (0-4) (Reference)  (Reference)  
CES-D, Mid (>4-9) 1.109 [0.659, 1.864]  1.465 [0.941, 2.280] 0.090  
CES-D, Higher (>9) 1.276 [0.730, 2.218]  1.63 [1.009, 2.651] 0.046  
I-6 (pg/ml) (low) (Reference)  (Reference)  
 IL-6 (pg/ml) (Higher) 2.767 [1.536, 4.98] 0.0007  2.339 [1.119, 3.775] 0.005  
Sleep Quality- Measured by Insomnia Scale (IS)    
   IS (No symptoms)-1 (Reference)  (Reference)  
   IS (Mild) -2 1.031 [0.633, 1.677]  0.914 [0597, 1.400]  
   IS (Daytime bother)-3 
1.197 [0.704, 2.038]  1.189 [0.751, 1.881]  
Note. High-Density Lipoprotein (HDL), Interleukin-6 (IL-6), Depressive symptoms (DEP S) / measured by CES-D 
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Data Analysis Aim 2 -The Effect of Gender 
 Analysis was conducted to prospectively evaluate whether gender modifies the 
relationships between sleep quality, depressive symptoms, and inflammation and long-
term risk of MACE.  Summary statistics on the participants and variables separated by 
gender is presented in Table 8a for females and Table 8b for males.  Student t-tests are 
reported for continuous variables, presented as mean and standard deviation.   
Categorical variables were analyzed with Chi-Square tests and presented as 
frequencies and percentages.  In comparing the overall gender specific summary 
statistics, no significant differences were identified. To examine the effects of gender on 
the relationships between depressive symptoms inflammation and insomnia symptoms, 
models were run to test for interaction with gender. 
Effect of Gender and Depressive Symptoms on Risk for CVD 
Table 9 provides results from three tests for the effect of gender. The first model 
shown demonstrates a joint model where the variables gender and depressive 
symptoms are combined (multiplied) in relation to predicting MACE (i.e. Females with 
high depressive symptoms).  Wald chi-square test for these tests were not significant.  
However, this approach to investigating effect modification is often underpowered and 
inconclusive, in part, because joining these variables results in less precision and a 
large (e.g. four-fold) increase in the variance for the interaction term.   
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Table 8a.   
Descriptive Statistics of Participants by Gender (Females) 
  MACE1 MACE6 
FEMALES Yes No p-value Yes No p-value 
Parameter n=55 n=1201  n=76 n=1180  
Age M/SD 62.65 ± 7.81 58.55 ± 7.40 <0.001  63.79 ± 7.64 58.40 ± 7.33 <0.001  
%Female 55 (48.67) 1201 (67.40) <0.001  76 (47.50) 1180 (68.01) <0.001  
Race   0.976   0.674 
   White 30 (54.55) 642 (53.46)  38 (50.0) 634 (53.73)  
   Black 24 (43.6) 533 (44.38)  37 (48.68) 520 (44.07)  
   Other       
BMI kg/m2 M/SD 30.15 ± 6.32 30.19 ± 6.71 0.966 29.71 ± 589 30.22± 6.74 0.519 
Waist in cm 94.68 ±15.88 93.69±15.43 0.648 95.51±15.88 93.68±15.42 0.658 
Smoking   0.868   0.377 
   Current smoker 6 (10.91) 108 (9.07) 0.01 10 (13.16) 104 (8.89)  
   Former smoker 21 (38.18) 485 (40.72)  27 (35.53) 479 (40.94)  
   Never smoker 28 (50.91)  598 (50.21)  39 (51.32) 587 (50.17)  
Diabetes  109 (9.13) 0.008 15 (19.74) 105 (8.98) <0.002 
Systolic Blood Pressure 
(mmHg)  142.8 ±19.18 135.3±20.09 0.007  142.0±19.23 135.2±20.10 0.004  
Hypertensive meds 30 (54.55) 487 (40.58) 0.040  39 (51.32) 478(40.54) 0.064 
HDL 57.98 ±12.45 61.51±14.99 0.086  60.70±13.56 61.39±14.98 0.699 
Triglycerides 134.3 ±63.57 120.2±75.39 0.172 123.3±63.46 120.7±75.63 0.771 
Statin medication 13 (23.64) 217 (18.08) 0..298 18 (23.68) 212 (17.98) 0.213 
Glucose 106.4±40.27 96.94±24.93 0.008  104.5±25.73 96.91. ±25.7 0.014 
IL-6   0.067    0.031 
Lowest tertile 9 (18.00) 336 (30.08)  12 (17.91) 333 (30.27)  
Upper two tertiles 41 (82.00) 781 (69.92)  55 (82.09) 767 (69.73)  
Depressive symptoms   0.138   0.214 
CES-D, Low (0-4) 13 (23.64) 391 (32.97)  18 (24.00) 386 (33.10)  
CES-D, Mid (>4-9) 16 (29.09) 384 (32.38)  25 (33.33) 375 (32.16)  
CES-D, Higher (>9) 26 (17.27) 411 (34.65)  32 (42.67) 405 (34.73)  
Sleep Quality- Measured by Insomnia Scale (IS) 0.502   0.999 
   IS (No symptoms)-1 24 (50.00 639 (58.14)  38 (57.58) 625 (57.82)  
   IS (Mild) -2 12 (25.00) 246 (22.38)  15 (22.73) 243 (22.48)  
   IS (Daytime bother)-3 12 (2500) 214 (19.47)  13 (19.70) 213 (19.70)  
Note.  'Insomnia Category 1. Low frequency of or no complaints, 'Insomnia Category 2. High frequency of complaints, low bother Insomnia 
Category 3. High Frequency of complaints, high bother.  Blood Pressure (BP) 
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Table 8b.   Descriptive Statistics of Participants by Gender (Males) 
MALES MACE1 MACE6 
Parameter 
Yes 
n=58 
No 
n=581 p-value 
Yes 
n=84 
No 
n=555 p-value 
Age Mean/SD 62.97 ± 7.09 58.79 ± 7.46 <0.001  62.71 ± 7.30 58.63 ± 7.41 <0.001  
Race   0.976   0.674 
   White 34 (58.62) 341(58.69)  47 (55.95) 328 (59.10)  
   Black 23 (39.66) 219 (37.69)  37 (44.05) 205 (36.94)  
   Other 1 21  0 22  
BMI kg/m2 M/SD  30.94 ± 6.38 29.63 ± 5.56 0.095 30.76 ±7.03 29.60± 5.40 0.081  
Waist in cm 104.5 ±13.76 99.57 ±13.62 0.009  103.3 ± 15.48 99.54 ± 13.35 0.021  
Smoking   0.107   0.001 
   Current smoker 9 (15.52) 69 (11.98)  19 (22.89) 59 (10.71)  
   Former smoker 31 (53.45) 245 (42.53  40 (48.19) 236 (42.83)  
   Never smoker 18 (31.03) 262 (45.49)  24 (28.92) 265 (46.46)  
Diabetes Mellitus 13 (22.81) 48 (8.30) <0.001  14 (16.87) 47 (8.51) 0.016 
Systolic BP (mmHg) 145.5 ±22.17  136.8 ±17.68  0.001  143.4 ±20.91  136.7 ±17.71  0.002   
Takes BP meds 29 (50.00) 213 (36.92) 0.051 B 40 (47.62) 202 (36.66) 0.054  
HDL 49.14 ±12.10 50.70 ± 12.13 0.35 50.27 ± 14.29 50.60 ±11.78 0.816 
Triglycerides 119.1 52.88 128.4±79.1 0.379 12.87±93.16 127.74.50 0.881 
Statin medication 17 (29.31) 119(20.62) 0.125 18 (21.43) 118(21.42) 0.998 
Glucose 104.4 ± 22.43 101.0 ± 25.90 0.333 133.6 ± 21.52 101. ± 26.16 0.387 
IL-6    <0.001   <0.001   
Lowest tertile 8 (16.33) 232 (43.04)  15 (20.27) 225 (43.77)  
Upper two tertiles 41 (83.67) 307 (56.96)  59 (79.73) 289 (56.23)  
Depressive symptoms   0.138   0.214 
CES-D, Low (0-4) 25 (43.10) 250 (43.55)  30 (36.14) 245 (44.63)  
CES-D, Mid (>4-9) 19 (32.76) 160 (27.87)  29 (34.94) 150 (27.32)  
CES-D, Higher (>9) 14 (24.14) 164 (28.57)  24 (28.92) 154 (28.05)  
Sleep Quality- Measured by Insomnia Scale (IS) 0.661   0.624 
  IS (No symptoms)1 40 (71.43) 352 (65.55)  55 (68.75) 337 (65.69)  
  IS (Mild) -2 10 (17.86)  110 (20.48)   13 (16.25)  107 (20.86)   
  IS (Daytime bother)3 6 (10.71  75 (13.97)   12 (15.00)  69 (13.45)   
Note.  'Insomnia Category 1. Low frequency of or no complaints, 'Insomnia Category 2. High frequency of complaints, low bother Insomnia 
Category 3. High Frequency of complaints, high bother.  Blood Pressure (BP) 
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The next test for effect modification by gender is a stratified model. In other words, 
genders are separated for analysis. This model illustrates females with higher 
depressive symptoms have nearly double the risk for MACE1 (HR=1.95) and MACE6 
(HR=1.82).    
  
 
Table 9.  Gender by Depressive Symptoms Interaction on MACE 
 MACE1 MACE6 
Parameter 
Haza
rd 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
DEP S  p-values       
Gender X Mid (CES-D)   0.686   0.905 
Gender x High (CES-D)    0.185   0.704 
DEP S– Female      
      (CES-D) Low (0-4) (Reference)   (Reference)  
      (CES-D) Mid (>4-9) 1.376 [0.661, 2.865] 0.69 1.703 [0.919, 3.157] NS 
      (CES-D) Higher (>9) 1.957 [0.999, 3.834] 0.06 1.820 [1.000, 3.312] 0.04 * 
DEP S- Male      
     (CES-D) Low (0-4) (Reference)  (Reference)  
     (CES-D) Mid (>4-9) 1.131 [0.616, 2.075] NS 1.621 [0.961, 2.734] 0.07 
     (CES-D) Higher (>9) 1.035 [0.532, 2.014] NS 1.551 [0.885, 2.727] 0.124 
Gender by DEP S       
    Female x Low (CES-D)  (Reference)  (Reference)  
    Male x Low (CES-D) 2.50 [1.265, 4.979] ** 2.533 [1.368,   4.687] ** 
    Female x Mid (CES-D) 1.376 [0.661, 2.856] NS 1.703   [0.919,   3.157] B 
    Male x Mid (CES-D) 2.838 [1.370, 5.880] ** 4.105 [2.211,   7.622] *** 
    Female x High (CES-D) 1.957 [0.999, 3.834] * 1.820   [1.000,   3.312] * 
    Male x High (CES-D) 2.597 [1.192, 5.658] * 3.935 [2.050,   7.553] *** 
Note. ***, **, * denotes significant, p=<0.001, p<=0.01, p<=0.05, respectively. B denotes significance is borderline 
or close to significant, 0.05 =<p<0.1   Depressive symptoms (DEP S) 
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 Therefore, females with depressive symptoms within the highest tertile of (CES-
D) scores are at an increased risk for developing CVD compared to females with low 
levels of depressive symptoms. For men, depressive symptoms were not a significant 
predictor of MACE, however the hazard ratios were >1 indicates a suggestion of 
depression being associated with risk of MACE in males. The third analysis created 
indicator variables for combinations of gender and tertiles of depression. Males at every 
level (i.e. irrespective of level of depressive symptoms) had a higher risk of MACE as 
compared to women.  Overall, results indicated that depressive symptoms were 
associated with higher risk of MACE in both genders, while not significantly different 
between genders.  
 
Table 10. Gender by IL-6 Interaction on MACE 
 MACE1 MACE6 
Parameter 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Gender x IL-6 
Interaction  
  0.208   0.368 
Effect of IL-6 High x 
Low     
Among Females 1.717 [0.822, 3.586] NS 1.688 [0.893, 3.193] NS 
Among Males 3.441 [1.529, 7.744] ** 2.506 [1.383, 4.541] ** 
Gender x IL-6 Combination    
     Low IL-6 x Female (Reference)  (Reference)  
     Low IL-6 x Male 1.036 [0.380, 2.822] NS 1.740 [0.793, 3.816] NS 
     High IL-6 x Female 1.717 [0.822, 3.586] NS 1.688 [0.893, 3.193] NS 
     High IL-6 x Male        3.564 [1.662, 7.639] ** 4.360 [2.258, 8.416] *** 
RERI Male IL-6 
Interaction 
3.564-1.036-1.717+1 = 
1.811 0.29 
4.360 -1.740-1.688+1 
=1.932 
0.026 
* 
Note. ***, **, * denotes significant, p=<0.001, p<=0.01, p<=0.05, respectively. B denotes significance is 
borderline or close to significant, 0.05 =<p<0.1 
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Effect of Gender on Inflammation /IL-6 
 As indicated in stratified analysis in Table 10, the effect of high IL-6 on long term 
risk of CVD was substantial and was higher in males than in females.  Specifically, for 
MACE1, a high IL-6 in males resulted in an adjusted hazard ratio of 3.56 in males 95% 
CI [1.66, 7.64] as compared to an adjusted hazard ratio of 1.72 in females, 95% CI 
[0.82, 3.59]. Corresponding estimates for the MACE 6 definition were 4.36 in males 
95% CI [2.26, 8.42] compared to 1.69 in females, 95% CI [0.89, 3.19]. Although these 
apparent gender differences did not reach statistical significance in the formal test of 
interaction, the evidence indicated that high IL-6 is a strong independent risk factor for 
long-term risk of CVD, particularly in males.  
 The calculation of the relative excess risk due to interaction (RERI) computed by 
the delta method is shown at the bottom of Table 10 (Li & Chambless,2007). The RERI 
for being male and having high IL-6 was 1.81 for MACE1 and 1.93 for MACE6, 
indicating a near double of risk among males. 
Effect of Gender on Sleep Quality 
 Sleep quality measured by Insomnia questionnaire on all three categories of 
sleep quality was not a significant risk factor for MACE for either gender (Table 11).  
The differences in the ratios for males and females did not reach statistical significance 
(all interaction p-values were greater than 0.15).  Moreover, for males, hazard ratio 
estimates for long-term risk of CVD in relation to insomnia were below the null value of 
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1.0, thereby indicating no increased risk. For females, hazard ratios associated with 
insomnia were only nominally above the null value of 1.0, again, indicating essentially 
no exceed risk of CVD.   
 
 
 
Table 11.  Gender by Sleep Quality Interaction on MACE 
 MACE1 MACE6 
Parameter 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Hazard 
Ratio 
95% HR 
Confidence 
Interval  Sig 
Interaction p-values     
Gender x Insomnia 2  0.183  0.251 
Gender x Insomnia-3   0.204  0.917 
   Among Females     
      Category 1  (Reference)   (Reference)  
      Category 2 1.477 [0.736, 2.964] NS 1.191 [0.652, 2.177] NS 
      Category 3 1.668 [0.830, 3.354] NS 1.175 [0.609, 2.265] NS 
   Among Males       
      Category 1 (Reference)   (Reference)  
      Category 2 0.756 [0.377, 1.519] NS 0.720 [0.893, 3.193] NS 
      Category 3 0.811 [0.340, 1.934] ** 1.233 [0.650, 2.339] *** 
Gender x Insomnia        
Insomnia 1 x Female (Reference)  (Reference)  
Insomnia 1 x Male 2.609 [1.540,   4.418] *** 2.623 [1.691,   4.069] *** 
Insomnia 2 x Female 1.477   [0.736,   2.964] NS 1.191 [0.652,   2.177] NS 
Insomnia 2 x Male 1.973 [0.925,   4.208] B 1.889 [0.986,   3.619] B 
Insomnia 3 x Female 1.668 [0.830,   3.354] NS 1.175 [0.609,   2.265] NS 
Insomnia 3 x Male 2.115 [0.849,   5.265] NS 3.234   [1.653,   6.328] *** 
Note. 'Insomnia Category 1. Low frequency of or no complaints, 'Insomnia Category 2. High frequency of 
complaints, low bother Insomnia Category 3. High Frequency of complaints, high bother. '***, **, * -HR is 
significant, p=<0.001, p<=0.01, p<=0.05, respectively. B - HR is borderline or close to significant, 0.05 =<p<0.1   
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Summary 
 In summary, depressive symptoms were associated with a modest long-term risk 
of CVD in both males and females.  High inflammation (IL-6) was associated with 
substantially higher long-term risk of CVD, particularly in males. Insomnia was not 
predictive of risk of CVD in this study.  In conclusion, it would be suggested that 
depressive symptoms and inflammation may be considered in the future as screening 
targets for risk of CVD.  
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CHAPTER FIVE: 
DISCUSSION 
 Chapter Five includes a synthesis of the study results, discussion and 
implications for nursing practice and recommendations for future research.  The 
purpose of this study was to assess the effects of depressive symptoms, inflammation, 
and quality of sleep on the risk for developing cardiovascular disease (CVD), while 
additionally testing for differences among gender.  The goal was to determine if any of 
these factors should be considered for use in the future for routine preventative 
screening for CVD risk.   
 Traditional Risks for CVD 
This secondary analysis included a well-represented sample including, 66% females 
and 34% males with a mean age of 61 years and range from 47-75 years of age. Age 
was a significant predictor of MACE, which would be expected based on previously 
published studies. Increasing age has an increased effect on many risk factors for CVD 
such as central obesity, blood pressure, hyperlipidemia, insulin resistance, 
inflammation, and endothelial dysfunction (Dhingra & Vasan, 2012; Lopez-Candales et 
al., 2017; Yang et al., 2015).   Men in this study were at nearly two-times the risk for 
MACE. This supports previous findings with men being at a greater risk than women for 
CVD within similar middle-aged populations (Maas & Appelman, 2010; Mosco, Barrett-
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Connor & Wenger, 2011; Benjamin et al., 2018).  However, it has been reported that 
differences among the genders decrease as age increases (Maas & Appelman, 2010; 
Mehta et al., 2016; Mosco, Barrett-Connor & Wenger, 2011; Benjamin et al., 2018). 
While many studies have had underrepresentation of Blacks, by purposeful 
oversampling, this study included 46% Blacks. Race was not a significant independent 
predictor of the development of CVD within this population group.  
The traditional risk factors evaluated were consistent with previous research. The 
effect of smoking doubled the risk for developing MACE in this population.  Our findings 
support previous studies including a meta-analysis of 25 studies among varying 
populations (Mons, et al., 2015).  Despite the relatively small number of diabetics within 
the Heart SCORE cohort (9%), nearly every model tested yielded a significant effect 
from diabetes. Studies looking at the effect of diabetes on CVD have reported a 2-fold 
risk of CVD when compared to non-diabetics (Anderson et al., 2001; Badescu et al., 
2016; Ivanos et al., 2018).  These findings are consistent with our findings with diabetics 
being at 2.3 times the risk for MACE1 and 2.08 for MACE6. Despite several studies 
supporting the association between lower levels of HDL cholesterol and higher levels of 
triglycerides being predictive of long-term CVD risk (Klempfer et al., 2016; Miller, 2009), 
the present analysis found only minimal evidence for these relationships. 
Systolic blood pressure was associated with risk for CVD in this analysis which is 
consistent with evidence of systolic blood pressure being a main predictor of CVD in a 
number of studies (Goldstein et al., 2014; Wong et al., 2012). Controlling blood pressure 
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at even a small range has been found to be beneficial in reducing these risks (Whelton 
et al., 2017). 
Novel Risk Factors  
 Previous literature suggests that several novel risk factors, including depressive 
symptoms, inflammation, and sleep quality may influence the risk for having a major 
adverse cardiac event. Additionally, prior research suggests these factors affect 
outcomes and risk of mortality among those who have already developed CVD (Celano 
& Huffman, 2011; Mehta et al., 2016; Rutledge et al., 2006).  
 The effect of depressive symptoms was of considerable interest in the present 
analysis, particularly with respect to potential recommendations for both primary and 
secondary prevention of CVD. The addition of depressive symptoms to the initial 
traditional risk factor model increased the risk for MACE by more than 1.5 times, with 
estimates generally similar between men and women. Mixed results regarding an effect 
of gender and depressive symptoms have been reported. Evidence indicates a higher 
prevalence of depressive symptoms in women than in men (Vaccarino & Brenner, 
2016).  Despite the higher prevalence rates, the effects of depressive symptoms on 
MACE did not significantly differ between genders (Vaccarino & Brenner, 2016). The 
present findings support similar findings reported by Ivanovs et al. (2018), where 
depressive symptoms were a significant predictor in a sample of 1,500 persons HR  
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1.57, 95% CI [1.06, 2.33]; p= 0.03, and significant predictor of cardiac related death HR  
3.2, 95% CI [1.2, 8.9]; p=0.025 (Ivanovs et al., 2018; Lahtind et al., 2018).  
 Inflammation, as measured with IL-6, was strongly associated with increased 
long-term risk of MACE among participants in the Heart Score cohort, especially in men. 
High inflammation has been associated with higher risk for cardiovascular events and 
death post event (Held et al., 2017; Nishida et al., 2011; Riker et al., 2000). The present 
finding of a particularly substantial risk of MACE in men in relation to high inflammation 
does not appear to have been widely reported in the literature. 
 Insomnia was not associated with long-term risk of CVD in this study.  However, 
persons with difficulty falling asleep, staying asleep, and having daytime bother have 
been identified to be at higher risk for developing CVD in other studies (Hoevenaar-
Blom et al., 2011).    
 Strengths and Limitations, Recommendations 
The Heart SCORE data set provided a plethora of data and the advantages of 
having longitudinal follow-up of risk of cardiovascular events over time. The commitment 
by study participants to follow through for over 10 years helped to ensure validity of the 
data. The study sample ages, gender, and racial mix were fairly balanced among the 
participants which helps to aid in generalizability of results.  
 Study limitations include the overall good health of this community-based study 
population and hence relatively low rates of MACE. The population group was obtained 
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from a community population with similar backgrounds and relatively similar social 
economic status and lifestyles.  Although there was racially nearly equal representation 
between whites and blacks, results from this population may not be generalizable to a 
larger population or compared to the US population. Possible reasons for this potential 
lack of generalizability included that this group was self-selected, mostly insured, had a 
relatively low rate of smokers (13%) that was than the national average (14.5%) 
(Benjamin et al., 2018).  
 Another limitation to this study is that the cut points chosen for depressive 
symptoms did not reflect standard cut points used for screening. In this analysis, the 
effect of depressive symptoms was significant at the highest tertile of depressive 
symptoms, (CES-D) Higher (>9), This range for the highest tertile represents relatively 
low scores as compared to the CESD score greater than 16 that indicates the presence 
of depressive symptoms consistent with depression (Radloff, 1997; Fischer, 2009). The 
lower cut points were chosen due to the sparse numbers of persons within the range of 
depressive symptoms consistent with a diagnosis of depression.  Specifically, in this 
population, depressive symptoms were low; the mean CES-D score for women was 
(8.0) and the mean score for men was (5.6).  Larger samples sizes and populations with 
an increased risk for CVD have been found to have increased prevalence of depression 
(Piwonski, Piwonska, & Sygnowska, 2014).  
 The inflammatory markers, including both CRP and IL-6, were only drawn at 
baseline.  Using one value to predict long-term outcomes (i.e. CVD) may yield 
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difficulties related to the causes of elevation from a single measurement. Both markers 
are acute phase reactions, such as a recent illness or injury, and thus, an elevated IL-6 
value from a single measurement may not be indicative of chronic inflammation.  It 
would be suggested that IL-6 be measured annually to assess for chronicity of high 
inflammation. 
 Sleep quality was not associated with long-term risk of CVD.  However, data 
collection for this measure was not optimal. Specifically, there was a great deal of 
missing data with this instrument, including missing data on duration of the problem.  
Completing multiple self-reports on follow up visits may lead to response fatigue, 
resulting in missing data and inaccurate responses (O’Reilly, 2017).  
Implications for Nursing Practice 
 In summary, the purpose of this study was to estimate long-term risk of CVD in 
relation to novel factors including depressive symptoms, inflammation, and quality of 
sleep.  Based on findings from this study, there are no firm global recommendations 
regarding changes to screening processes for CVD risk.  However, evidence from this 
study showed that depressive symptoms were generally predictive of CVD in both men 
and women. Therefore, because depression is associated with poorer outcomes and 
mortality after a significant cardiovascular event, it is suggested that health providers, 
when considering an individualized patient centered approach, maintain a keen 
awareness of persons most likely to be at risk. Most screening tools for depressive 
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symptoms are available for free and involve a minimum time investment.  In addition to 
standard risk evaluation such as the Pooled Cohort Risk Equations, providers may wish 
to screen for depressive symptoms in selected individuals as part of preventative 
healthcare visits.    
 Inflammation was highly predictive of long-term risk of CVD, especially in men. 
Therefore, like depressive symptoms, screening for inflammation should be considered 
on an individual basis.  Screening with a laboratory test for IL-6 may prove to be a 
valuable tool in the prediction of CVD, especially in men.   
 Although not evident in this study, the literature suggests that insomnia with long 
duration and high symptoms of bother are associated with risk of CVD (Sands-Lincoln 
et al., 2012). Additional evidence is needed in this area to support routine screening for 
insomnia.  The use of quantitative measures such as sleep actigraphy in addition to the 
self-reported insomnia score may yield more accurate data.  
 It is recommended that the findings from this study and previous studies be 
considered, when conducting risk assessments.  A keen awareness of the effects of 
these novel risks factors allows for individualized approached for health screenings and 
educational opportunities for persons at risk. 
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